Abdelhadi M, Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998 Nov;83(11):3845-3851.
Abitbol C, Chan JC, Trachtman H, Strauss J, Greifer I. Growth in children with moderate renal insufficiency: measurement, evaluation, and treatment. J Pediatr 1996 Aug;129(2):s3-s8.
Abitbol CL, Warady BA, Massie MD, Baluarte HJ, Fleischman LE, Geary DF, Kaiser BA, McEnery PT, Chan JC. Linear growth and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: A report of the Growth Failure in Children with Renal Diseases Study. J Pediatr 1990 Feb;116(2):S46-S54.
Abrams P, Klevmark B. Frequency volume charts: An indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996;179:47-53.
Abugassa S, Nordenstrom J, Eriksson S, Mollerstrom G, Alveryd A. Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery 1990 Feb;107(2):128-133.
Acchiardo SR, Moore LW, Cockrell S. Does low protein diet halt the progression of renal insufficiency? Clin Nephrol 1986 Jun;25(6):289-294.
Ahn JH, Yoon KS, Lee WI, Suh JT, Lee TW, Ihm CG, Kim MJ. Bone marrow findings before and after treatment with recombinant human erythropoietin in chronic hemodialyzed patients. Clin Nephrol 1995 Mar;43(3):189-195.
Akiba T, Ando R, Kurihara S, Heishi M, Tazawa H, Marumo F. Is the bone mass of hemodialysis patients genetically determined? Kidney Int Suppl 1997 Nov;62:S69-S71.
Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998 Aug;32(2):238-246.
Akizawa T, Kinugasa E, Kitaoka T, Koshikawa S, Nakabayashi N, Watanabe H, Yamawaki N, Kuroda Y. Removal of beta-2-microglobulin by direct hemoperfusion with a newly developed adsorbent. ASAIO Trans 1987 Jul-Sep;33(3):532-537.
Akizawa T, Koshikawa S, Nakazawa R, Yoshida T, Kaneko M, Nitadori Y. Elimination of beta 2-microglobulin by a new polyacrylonitrile membrane dialyser: Mechanism and physiokinetics. Nephrol Dial Transplant 1989;4(5):356-365.
Albertson DA, Poole GV Jr, Myers RT. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism. Am Surg 1985 Jan;51(1):16-20.
Albertucci M, Zielinski CM, Rothberg M, Sterpetti A, Klingman R, Ronk JF. Surgical treatment of the parathyroid gland in patients with end-stage renal disease. Surg Gynecol Obstet 1988 Jul;167(1):49-52.
Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58(1):396-369.
Alexander PT, Schuman ES, Vetto RM, Gross GF, Hayes JF, Standage BA. Repeat parathyroid operation associated with renal disease. Am J Surg 1988 May;155(5):686-689.
Almqvist S, Hjern B, Wasthed B. The diagnostic value of a radioimmunoassay for parathyroid hormone in human serum. Acta Endocrinol (Copenh) 1975 Mar;78(3):493-509.
Alon U, Davidai G, Bentur L, Berant M, Better OS. Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 1986;12(5-6):320-325.
Altmann P, Plowman D, Marsh F, Cunningham J. Aluminium chelation therapy in dialysis patients: Evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Lancet 1988 May 7;1(8593):1012-1015.
Ambrosoni P, Heuguerot C, Olaizola I, Acuna G, Fajardo L, Petraglia A, Caorsi H, Lopez J, Kurdian M, Jorgetti V, Aznarez A. Can we use 99mTc-MIBI in functional studies of the parathyroid gland? Nephrol Dial Transplant 1998;13(Suppl 3):33-36.
Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999 Nov;34(5):875-883.
Ando A, Orita Y, Nakata K, Fukahara Y, Mikami, Jujii M, Nakajima Y, Ueda N, Abe H. The effect of essential amino acid supplementation therapy on prognosis of patients with chronic renal failure estimated on the basis of the markov process. Med J Osaka Univ 1981 Jan 1;32:31-37.
Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987 Mar;9(3):206-210.
Andresen J, Nielsen HE. Osteonecrosis and spontaneous fractures following renal transplantation. A longitudinal study of radiological bone changes and metacarpal bone mass. Acta Orthop Scand 1981 Aug;52(4):397-404.
Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW, Sherrard DJ. Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 1987 Dec;2(6):525-531.
Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, Coburn JW, Sherrard DJ. Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 1987 Jun;31(6):1344-1350.
Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989 Aug 3;321(5):274-279.
Angeli M, Wong LL, Myers SA, Wong LM, Pasieka JL, Roe MS, Duh QY. Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery 1997;122(6):1083-1090.
Aollin AW, Hart LK. The relationship of health belief motivations, health locus of control and health valuing to dietary compliance of hemodialysis patients. AANNT J 1982 Oct;9(5):41-47.
Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int 2000 Sep;58(3):981-988.
Ardissino G, Schmitt CP, Testa S, Claris-Appiani A, Mehls O. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Pediatr Nephrol 2000 Jul;14(7):664-668.
Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 1997;63(3):380-386.
Arons JA, Collins N, Arons MS. Results of treatment of carpal tunnel syndrome with associated hourglass deformity of the median nerve. J Hand Surg [Am] 1999 Nov;24(6):1192-1195.
Asad SN, Olmer AJ, Letteri JM. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis. Miner Electrolyte Metab 1984;10(5):333-336.
Asaka M, Iida H, Entani C, Fujita M, Izumino K, Takata M, Seto H, Sasayama S. Total and regional bone mineral density by dual photon absorptiometry in patients on maintenance hemodialysis. Clin Nephrol 1992 Sep;38(3):149-153.
Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999 Feb;33(2):287-293.
Aubia J, Bosch J, Lloveras J, Chine M, Hojman L, Masramon J. Relative hyperphosphaturia in diabetic chronic renal failure: A protective factor of hyperparathyroidism. Miner Electrolyte Metab 1987;13(5):311-315.
Aubia J, Serrano S, Marinoso L, Hojman L, Diez A, Lloveras J, Masramon J. Osteodystrophy of diabetics in chronic dialysis: A histomorphometric study. Calcif Tissue Int 1988 May;42(5):297-301.
Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F. ‘Pulse oral’ versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study [published erratum appears in Nephron 1998 Aug;79(4):509]. Nephron 1997;77(3):267-272.
Bagnis C, Dutto F, Gabella P, Vitale C, D’elia P, Marangella M, Ramello A. Biochemical and hormonal short-term effects of 25-hydroxyvitamin D in patients on continuous peritoneal dialysis. Ital J Miner Electrolyte Metab 1998;12(3-4):73-76.
Bailey GL, Griffiths HJ, Mocelin AJ, Gundy DH, Hampers CL, Merrill JP. Avascular necrosis of the femoral head in patients on chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972;18(0):401-404, 410.
Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH. Early therapy of renal bone disease with calcitriol: A prospective double-blind study. Kidney Int Suppl 1989 Nov;36(Suppl 27):S140-S142.
Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986 Oct;26(4):185-191.
Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med 1993 Oct;37(8):1035-1043.
Barata JD, D’Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996 Jan;11(1):125-132.
Bardin T. Low-dose prednisone in dialysis-related amyloid arthropathy. Rev Rhum Engl Ed 1994;61(9 Suppl):S97-S100.
Bardin T, Kuntz D, Zingraff J, Voisin MC, Zelmar A, Lansaman J. Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheum 1985 Sep;28(9):1052-1058.
Bardin T, Lebail-Darne JL, Zingraff J, Laredo JD, Voisin MC, Kreis H, Kuntz D. Dialysis arthropathy: Outcome after renal transplantation . Am J Med 1995 Sep;99(3):243-248.
Bardin T, Zingraff J, Drueke T, Kuntz D. Clinical aspects of beta-2 microglobulin amyloidosis, in Gejyo F, Brancaccio D, Bardin T (eds). Dialysis Amyloidosis. Milan, Italy, Wichtig Editore, 1989, pp 79-90.
Bardin T, Zingraff J, Shirahama T, Noel LH, Droz D, Voisin MC, Drueke T, Dryll A, Skinner M, Cohen AS. Hemodialysis-associated amyloidosis and beta-2 microglobulin. Clinical and immunohistochemical study. Am J Med 1987 Sep;83(3):419-424.
Barrientos A, Arteaga J, Rodicio JL, Alvarez Ude F, Alcazar JM, Ruilope LM. Role of the control of phosphate in the progression of chronic renal failure. Miner Electrolyte Metab 1982 Mar;7(3):127-133.
Barsotti G, Giannoni A, Morelli E, Lazzeri M, Vlamis I, Baldi R, Giovannetti S. The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 1984 Jan;21(1):54-59.
Barsotti G, Guiducci A, Ciardella F, Giovannetti S. Effects on renal function of a low-nitrogen diet supplemented with essential amino acids and ketoanalogues and of hemodialysis and free protein supply in patients with chronic renal failure. Nephron 1981;27(3):113-117.
Barsotti G, Lazzeri M, Cristofano C, Cerri M, Lupetti S, Giovannetti S. The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab 1986;12(2):103-106.
Barsotti G, Lazzeri M, Polloni A, Morelli E, Giovannetti E, Lupetti S, Cupisti A, Dani L, Giovannetti S. Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus. Adv Exp Med Biol 1986;208:493-499.
Barsotti G, Morelli E, Giannoni A, Guiducci A, Lupetti S, Giovannetti S. Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial. Kidney Int Suppl 1983 Dec;16:S278-S284.
Barth RH, Cheigh JS, Sullivan JF, Chami J, Suthanthiran M, Stubenbord WT, Stenzel KH, Rubin AL. The advantage of measurement of intact PTH in the prediction of clinical response and calcium metabolism after subtotal parathyroidectomy for renal osteodystrophy. Trans Am Soc Artif Intern Organs 1983;29:124-128.
Belon C, Dumas R, Tau C, Sabatier R, Bourdeau A, Garabedian M. [Dysregulation of plasma 1,25(OH)2D in calcium restriction in hypercalciuric children]. Arch Fr Pediatr 1992 Jun-Jul;49(6):519-524.
Benz RL, Siegfried JW, Teehan BP. Carpal tunnel syndrome in dialysis patients: Comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 1988 Jun;11(6):473-476.
Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis [letter]. Lancet 1987 Mar 14;1(8533):628-629. [letter]
Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 1978 Jun;88(6):774-780.
Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RR. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Contrib Nephrol 1980;18:72-81.
Berlyne GM. Calcium carbonate treatment of uremic acidosis. Isr J Med Sci 1971 Nov;7(11):1235-1239.
Berlyne GM, Hocken AG. Three years experience of a low protein diet in chronic renal failure. The dietary treatment of chronic renal failure, in Berlyne GM (eds): Nutrition in Renal Disease, Proceedings of a Conference Held at The University of Manchester, June 29-30, 1967. Edinburgh, UK, E & S Livingstone Ltd, 1968, pp 38-54.
Bessell JR, Proudman WD, Parkyn RF, Disney AP. Parathyroidectomy in the treatment of patients with chronic renal failure: A 10-year review. Br J Surg 1993 Jan;80(1):40-42.
Better OS, Kleeman CR, Gonick HC, Varrady PD, Maxwell MH. Renal handling of calcium, magnesium and inorganic phosphate in chronic renal failure. Isr J Med Sci 1967 Jan-Feb;3(1):60-79.
Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L. Aluminum induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989 Nov;36(5):852-858.
Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R, Buccianti G. Bone mass status in different degrees of chronic renal failure. Bone 1992;13(3):225-228.
Billotey C, Sarfati E, Aurengo A, et al. Advantages of SPECT in technetium 99m sestamibi parathyroid scintigraphy. J Nucl Med 1996;37:1773-1778.
Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant 1999 Jun;14(6):1475-1479.
Blackburn SL. Dietary compliance of chronic hemodialysis patients. J Am Diet Assoc 1977 Jan;70(1):31-37.
Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999 Apr;33(4):694-701.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998 Apr;31(4):607-617.
Blocklet D, Martin P, Schoutens A, Verhas M, Hooghe L, Kinnaert P. Presurgical localization of abnormal parathyroid glands using a single injection of technetium-99m methoxyisobutylisonitrile: Comparison of different techniques including factor analysis of dynamic structures. Eur J Nucl Med 1997 Jan;24(1):46-51.
Blodgett CJ. The process of adjustment in chronic renal failure and hemodialysis. Diss Abstr Int 1983;44(3B):905.
Blohme I, Eriksson A. Parathyroidectomy after renal transplantation. Scand J Urol Nephrol Suppl 1977;(42):134-136.
Blumberg A, Burgi W. Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987 May;27(5):245-249.
Bohm R, Gladziwa U, Clasen W, Riehl J, Mann H, Sieberth HG. Which bicarbonate concentration is adequate to lactate-buffered substitution fluids in maintenance hemofiltration? Clin Nephrol 1994 Oct;42(4):257-262.
Bonnin MR, Gonzalez MT, Huguet J, Rosel P, Navarro MA. 1,25-Dihydroxycholecalciferol as measured by a radioreceptor assay in normal subjects and patients after kidney transplantation. Clin Chem 1990 Feb;36(2):389-390.
Bonomini V, Albertazzi A, Bortolotti GC, Vangelista A. Effects of diet, dialysis and transplantation on bone lesions in chronic uraemia. Proc Eur Dial Transplant Assoc 1973;10(0):324-331.
Boran M, Cetin S. Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism [letter]. Nephron 1998 Sep;80(1):119-120. [letter]
Boran M, Doruk E, Gonenc F, Cetin S. 125 (OH) cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients. Int Urol Nephrol 1997;29(2):251-258.
Bouteiller G, Ton That H, Goudable C, Goffinet F, Heche JP, Orfila C, Suc JM. Amyloidosis in chronic hemodialysis: Rheumatological aspects. Contrib Nephrol 1988;62:67-74.
Boyle RM, Chinchilli VM, Shasky DA. Masking of physicians in the Growth Failure in Children with Renal Diseases Clinical Trial. Pediatr Nephrol 1993 Apr;7(2):204-206.
Brady JP, Hasbargen JA. Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 1998 Jan;31(1):35-40.
Brandi L, Daugaard H, Egsmose C, Tvedegaard E, Kjaerulff Nielsen P, Olgaard K. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med 1996 Apr;239(4):353-360.
Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, Olgaard K. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992;12(5):311-318.
Brandi L, Nielsen PK, Bro S, Daugaard H, Olgaard K. Long-term effects of intermittent oral alfacalcidol, calcium carbonate and low-calcium dialysis (125 mmol L) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. J Intern Med 1998;244(2):121-131.
Brazil M, Linderer RJ, Dickhans MJ, Garvin PJ. Aseptic hip necrosis after renal transplantation. Arch Surg 1986 Jul;121(7):803-805.
Brezin JH, Schwartz AB, Chinitz JL. Switch from acetate (Ac) to bicarbonate (Bi) dialysis: Better dialysis tolerance but failure to improve acidosis and hypertriglyceridemia (HTG). Trans Am Soc Artif Intern Organs 1985;31:343-348.
Briggs WA, Hampers CL, Merrill JP, Hager EB, Wilson RE, Birtch AG, Murray JE. Aseptic necrosis in the femur after renal transplantation. Ann Surg 1972 Feb;175(2):282-289.
Bro S, Brandi L, Olgaard K. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: Efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone. Nephrol Dial Transplant 1996 Aug;11(8):1586-1591.
Bro S, Brandi L, Olgaard K. Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids. Nephrol Dial Transplant 1996;11 Suppl 3:47-49.
Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 1998 Feb;31(2):257-262.
Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46(5):697-703.
Brouhard BH, Chan JC, Carter WH Jr. Final report of the Growth Failure in Children with Renal Diseases Study. J Pediatr 1996 Aug;129(2):s1-s3.
Brown EA, Gower PE. Joint problems in patients on maintenance hemodialysis. Clin Nephrol 1982 Nov;18(5):247-250.
Brunner FP, Brynger H, Ehrich JHH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G, Wing AJ. Case control study on dialysis arthropathy: The influence of two different dialysis membranes: Data from the EDTA Registry. Nephrol Dial Transplant 1990;5(6):432-436.
Buijsen CG, Struijk DG, Huijgen HJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Perit Dial Int 1996 Sep-Oct;16(5):497-504.
Caglar M, Adeera L. Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med 1999 Jun;13(3):141-145.
Calenoff L, Norfray J. Magnification digital roentgenography: A method for evaluating renal osteodystrophy in hemodialyzed patients. Am J Roentgenol Radium Ther Nucl Med 1973 Jun;118(2):282-292.
Campistol JM, Ponz E, Munoz-Gomez J, Oppenheimer F, Ricard MJ, Vilardell J, Andreu J. Renal transplantation for dialysis amyloidosis. Transplant Proc 1992 Feb;24(1):118-119.
Campos C, Arata RO, Mautalen CA. Parathyroid hormone and vertebral osteosclerosis in uremic patients. Metabolism 1976 May;25(5):495-501.
Canavese C, Barolo S, Gurioli L, Cadario A, Portigliatti M, Isaia G, Thea A, Marangella M, Bongiorno P, Cavagnino A, Peona C, Boero R, D’amicone M, Cardelli R, Rossi P, Piccoli G. Correlations between bone histopathology and serum biochemistry in uremic patients on chronic hemodialysis. Int J Artif Organs 1998;21(8):443-450.
Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J. Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998 Jun;13(6):1538-1542.
Caravaca F, Cubero JJ, Jimenez F, Lopez JM, Aparicio A, Cid MC, Pizarro JL, Liso J, Santos I. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. Nephrol Dial Transplant 1995;10(5):665-670.
Caravaca F, Fernandez MA, Ruiz-Calero R, Cubero J, Aparicio A, Jimenez F, Garcia MC. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998;13(10):2605-2611.
Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, Robles R, Sanchez-Casado E. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992;60(4):423-427.
Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000 Jul;36(1):160-166.
Cassidy MJ, Owen JP, Ellis HA, Dewar J, Robinson CJ, Wilkinson R, Ward MK, Kerr DN. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J M 1985 Jan;54(213):29-48.
Catizone L, Cocchi R, Fusaroli M, Zucchelli P. Relationship between plasma ß2-microglobulin and residual diuresis in continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit Dial Int 1993;13(Suppl 2):S523-S526.
Chan JC, Kodroff MB, Landwehr DM. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 1981 Oct;68(4):559-571.
Chan JC, McEnery PT, Chinchilli VM, Abitbol CL, Boineau FG, Friedman AL, Lum GM, Roy S 3rd, Ruley EJ, Strife CF. A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators. J Pediatr 1994 Apr;124(4):520-528.
Chan R, Gleim GW, DeVita MV, Zabetakis PM, Michelis MF. Effects of oral vs. intravenous calcitriol on serum parathyroid hormone levels in chronic hemodialysis. Dial Transplant 1993;22:736-739.
Chan YL, Furlong TJ, Cornish CJ, Posen S. Dialysis osteodystrophy. A study involving 94 patients. Medicine 1985;64(5):296-309.
Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F. Carpal tunnel syndrome and type of dialysis membrane. BMJ 1989 Apr 1;298(6677):867-868.
Chandran PK, Ulahannan TJ, Skiles M. Biochemical changes following parathyroidectomy. Int J Artif Organs 1993 Oct;16(10):700-703.
Channon SM, Arfeen S, Ward MK. Long-term accumulation of aluminum in patients with renal failure. Trace Elem Med 1988;5(4):154-157.
Chappuis P, de Vernejoul MC, Paolaggi F, Rousselet F. Relationship between hair, serum and bone aluminium in hemodialyzed patients. Clin Chim Acta 1989 Feb 22;179(3):271-278.
Charhon S, Yafi SE, Gaillard M, Beruard M, Janin G, Accominotti M, Traeger J, Meunier PJ. Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy. Contrib Nephrol 1988;64:160-169.
Charhon SA, Chavassieux P, Boivin G, Parisien M, Chapuy MC, Traeger J, Meunier PJ. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Clin Sci 1987 Aug;73(2):227-234.
Charhon SA, Chavassieux PM, Meunier PJ, Accominotti M. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis. Br Med J (Clin Res Ed) 1985 Jun 1;290(6482):1613-1614.
Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ. Serum bone Gla-protein in renal osteodystrophy: Comparison with bone histomorphometry. J Clin Endocrinol Metab 1986 Oct;63(4):892-897.
Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Chapuy MC, Meunier PJ. Serum bone gla-protein compared to bone histomorphometry in hemodialyzed patients. Adv Exp Med Biol 1986;208:291-296.
Charra B, Calemard E, Laurent G. Chronic renal failure treatment duration and mode: Their relevance to the late dialysis periarticular syndrome. Blood Purif 1988;6(2):117-124.
Chattopadhyay C, Ackrill P, Clague RB. The shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis. Br J Rheumatol 1987 Jun;26(3):181-187.
Chauveau P, Poignet JL, Kuno T, Bonete R, Kerembrun A, Naret C, Delons S, Man NK, Rist E. Phosphate removal rate: A comparative study of five high-flux dialysers. Nephrol Dial Transplant 1991;6 Suppl 2:114-115.
Chazan JA, Libbey NP, London MR, Pono L, Abuelo JG. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: A correlation between biochemical parameters and bone pathology findings. Clin Nephrol 1991;35(2):78-85.
Chazot C, Chazot I, Charra B, Terrat JC, Vanel T, Calemard E, Ruffet M, Laurent G. Functional study of hands among patients dialysed for more than 10 years. Nephrol Dial Transplant 1993;8(4):347-351.
Cheng IK, Lu HB, Chan CY, Cheng SW, Robinson JD, Tam SC, Lo WK, Cheung WC. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Clin Nephrol 1993 Aug;40(2):100-105.
Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Poly [allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997 Jan;29(1):66-71.
Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999 Jan;51(1):18-26.
Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 2000 Jul;10(3):125-132.
Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol 1996 Aug;7(8):1235-1240.
Chesney RW, Hamstra AJ, Mazess RB, Rose P, DeLuca HF. Circulating vitamin D metabolite concentrations in childhood renal diseases. Kidney Int 1982 Jan;21(1):65-69.
Chesney RW, Hamstra AJ, Phelps M, DeLuca HF. Vitamin D metabolites in renal insufficiency and other vitamin D disorders of children. Kidney Int Suppl 1983 Nov;15:S63-S69.
Chesser AM, Carroll MC, Lightowler C, Macdougall IC, Britton KE, Baker LR. Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure. Nephrol Dial Transplant 1997 Jan;12(1):97-100.
Cheung AK, Manolagas SC, Catherwood BD, Mosely CA Jr, Mitas JA 2d, Blantz RC, Deftos LJ. Determinants of serum 1,25(OH)2D levels in renal disease. Kidney Int 1983 Jul;24(1):104-109.
Chinchilli VM, McEnery PT, Chan JC. Statistical methods and determination of sample size in the Growth Failure in Children with Renal Diseases Study. J Pediatr 1990 Feb;116(2):S32-S36.
Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: Roles of parathyroid hormone and substance P . J Am Acad Dermatol 1997 Apr;36(4):538-543.
Chou FF, Chan HM, Huang TJ, Lee CH, Hsu KT. Autotransplantation of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism. Surgery 1998 Jul;124(1):1-5.
Chou FF, Lee CH, Lee CT. Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. World J Surg 1999 May;23(5):452-456; 456-457.
Christensen AJ, Smith TW. Personality and patient adherence: Correlates of the five-factor model in renal dialysis. J Behav Med 1995 Jun;18(3):305-313.
Christiansen C. Chronic renal failure and vitamin D metabolites: A status report. J Steroid Biochem 1983 Jul;19(1B):517-523.
Christiansen C, Christensen MS, Hartnack B, Melsen F, Transbol I, Rodbro P. Vitamin-D analogues and renal function [letter]. Lancet 1979 Jan 6;1(8106):50-51.
Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 1981 Jan;15(1):18-22.
Christiansen C, Rodbro P, Christensen MS, Hartnack B. Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol (Oxf) 1981 Sep;15(3):229-236.
Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978 Sep 30;2(8092 Pt 1):700-703.
Christiansen C, Rodbro P, Christensen MS, Naestoft J, Hartnack B, Transbool I. Decreased renal function in association with administration of 1,25- dihydroxyvitamin D3 to patients with stable, advanced renal failure. Contrib Nephrol 1980;18:139-146.
Chudek J, Karkoszka H, Schmidt-Gayk H, Ritz E, Kokot F. Plasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: Are they interrelated? J Nephrol 2000 Jan-Feb;13(1):54-58.
Chylkova V, Fixa P, Rozprimova L, Palicka V, Hartmann M, Erben J, Prochazkova J. Beta-2-microglobulin in patients with renal disease. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1988
Chylkova V, Fixa P, Rozprimova L, Palicka V, Hartmann M, Erben J, Prochazkova J. Beta-2-microglobulin in patients with renal disease. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1988
Cianciaruso B, Capuano A, D’Amaro E, Ferrara N, Nastasi A, Conte G, Bellizzi V, Andreucci VE. Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure. Kidney Int Suppl 1989 Nov;27:S173-S176.
Claeyssens S, Lavoinne A, Daragon A, Josse S, Godin M, Matray F, Kuhn JM. Total and ultrafiltrable plasma magnesium in hyper- and hypoparathyroidism, and in calcium-related metabolic disorders. Clin Chim Acta 1991 Jan 15;195(3):107-114.
Clark AG, Oner A, Ward G, Turner C, Rigden SP, Haycock GB, Chantler C. Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 1989;4(6):539-544.
Clark AG, Oner A, Ward G, Turner C, Rigden SPA, Haycock GB, Chantler C. Safety and efficacy or calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 1989;4(6):539-544.
Clark HO, Stark DA, Duh YQ, Arnaud DC, Gooding AW. Value of high resolution real-time ultrasonography in secondary hyperparathyroidism. Am J Surg 1985 Jul;150(1):9-17.
Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 2000 Nov;15(11):1841-1846.
Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm 1995 Sep 1;52(17):1895-1900.
Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990;38:554-561.
Coburn JW, Norris KC. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine. Semin Nephrol 1986 Dec;6(4 Suppl 1):12-21.
Cochran M, Bulusu L, Horsman A, Stasiak L, Nordin BE. Hypocalcaemia and bone disease in renal failure. Nephron 1973;10(2):113-140.
Cochrane methods working group on systematic review of screening and diagnostic tests: Recommended methods [book online]. Bedford Park (Australia): The Cochrane Collaboration, Australasian Cochrane Centre; 1996 Jun 6 [cited 1999 Jan 07]. [12p]. Available: http://som.flinders.edu.au/fusa/cochrane/.
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000 Dec;36(6):1115-1121.
Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, Pasquali M, Perruzza I, Sardella D, Spurio A. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 1992;12(4):246-251.
Coen G, Mazzaferro S, Ballanti P, Bonucci E, Cinotti GA, Fondi G, Manni M, Pasquali M, Perruzza I, Sardella D, et al. Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure. J Lab Clin Med 1993 Jul;122(1):103-109.
Coen G, Mazzaferro S, Ballanti P, Costantini S, Bonucci E, Bondatti F, Manni M, Pasquali M, Sardella D, Taggi F. Treatment with 1,25(QH)2D3 in predialysis chronic renal failure. Contrib Nephrol 1991;90:183-188.
Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 1996;11(5):813-819.
Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, Landi A, Smacchi A, Della Rocca C, Cinotti GA, et al. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab 1986;12(5-6):375-382.
Coen G, Mazzaferro S, Bonucci E, Taggi F, Ballanti P, Bianchi AR, Donato G, Massimetti C, Smacchi A, Cinotti GA. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. Kidney Int 1985 Nov;28(5):783-790.
Coen G, Mazzaferro S, Costantini S, Ballanti P, Carrieri MP, Giordano R, Smacchi A, Sardella D, Bonucci E, Taggi F. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment. Miner Electrolyte Metab 1989;15(5):295-302.
Coen G, Mazzaferro S, Manni M, Napoletano I, Fondi G, Sardella D, Perruzza I, Pasquali M, Taggi F. Treatment with small doses of 1,25-dihydroxyvitamin D in predialysis chronic renal failure may lower the rate of decline of renal function. Ital J Miner Electrolyte Metab 1994;8(3):117-121.
Coggins CH, Dwyer JT, Greene T, Petot P, Snetselaar LG, Van Lente F, Striker GE, Sandberg AM, Hirschman GH, Anderson A, Edington B, Norwood E. Serum lipid changes associated with modified protein diets: Results from the feasibility phase of the modification of diet in renal disease study. Am J Kidney Dis 1994;23(4):514-523.
Cohen ME, Cohen GF, Ahad V, Kaye M. Renal osteodystrophy in patients on chronic haemodialysis. A radiological study. Clin Radiol 1970 Apr;21(2):124-134.
Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989 Apr;8(4):441-454.
Coles GA, Gokal R, Ogg G, Jani F, O’Donoghue DT, Cancarinu GC, Maiorca R, Tranaeus A, Faict D, De Vos C. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997;17(1):48-51.
Combe C, Deforges-Lasseur C, Caix J, Pommereau A, Marot D, Aparicio M. Compliance and effects of nutritional treatment on progression and metabolic disorders of chronic renal failure. Nephrol Dial Transplant 1993;8(5):412-418.
Combe C, Morel D, de Precigout V, Blanchetier V, Bouchet JL, Potaux L, Fournier A, Aparicio M. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol). Nephron 1995;70(3):287-295.
Conceicao SC, Weightman D, Smith PA, Luno J, Ward MK, Kerr DN. Serum ionised calcium concentration: measurement versus calculation. Br Med J 1978 Apr 29;1(6120):1103-1105.
Conger JD, Hammond WS, Alfrey AC, Contiguglia SR, Stanford RE, Huffer WE. Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med 1975 Sep;83(3):330-336.
Cook TD, Campbell DT. Quasi-Experimentation design & analysis issues for field settings. Boston, MA, Houghton Mifflin Company, 1979. Quasi-experiments: nonequivalent control group designs. pp 95-146.
Copley JB, Hui SL, Leapman S, Slemenda CW, Johnston CC Jr. Longitudinal study of bone mass in end-stage renal disease patients: effects of parathyroidectomy for renal osteodystrophy. J Bone Miner Res 1993 Apr;8(4):415-422.
Coronel F, Lozano C, Herrero JA, Horcajo P, Marron B, Barrientos A. A prospective longitudinal study of bone densitometry in patients starting peritoneal dialysis. Perit Dial Int 1997;17(1):80-82.
Costantini S, Giordano R, Vernillo I, Piccioni A, Zapponi GA. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients. Ann Ist Super Sanita 1989;25(3):457-461.
Couttenye MM, D’haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997;12(10):2144-2150.
Couttenye MM, D’haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME. Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11(6):1065-1072.
Coyne T, Olson M, Bradham K, Garcon M, Gregory P, Scherch L. Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 1995 Nov;95(11):1301-1306.
Langman C. (Children’s Memorial Hospital, Chicago, IL). Personal communication. December 22, 2000.
Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000 Feb;35(2):227-236.
Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R. Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int 1999 May;55(5):2021-2029.
Cummings KM, Becker MH, Kirscht JP, Levin NW. Psychosocial factors affecting adherence to medical regiments in a group of hemodialysis patients. Med Care 1982 Jun;20(6):567-580.
Cundy T, Bartlett M, Bishop M, Earnshaw M, Smith R, Kanis JA. Plasma hydroxyproline in uremia: Relationships with histologic and biological indices of bone turnover. Metab Bone Dis Relat Res 1983;4(5):297-303.
Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA. Who gets renal bone disease before beginning dialysis? Br Med J (Clin Res Ed) 1985 Jan 26;290(6464):271-275.
Cushner HM, Copley JB, Lindberg JS, Foulks CJ. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF [published erratum appears in Kidney Int 1988 May;33(5):1047]. Kidney Int 1988 Jan;33(1):95-99.
D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger H-W, Kalayoglu M, Vernon WB, Belzer FO, Starling JR. Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989;106(6):1049-1056.
D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR. Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989 Dec;106(6):1049-55; discussion 1055-.
D’Amico G, Gentile MG, Fellin G, Manna G, Cofano F. Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. Nephrol Dial Transplant 1994;9(11):1590-1594.
D’Haese PC, Clement JP, Elseviers MM, Lamberts LV, Van de Vyver FL, Visser WJ, De Broe ME. Value of serum aluminium monitoring in dialysis patients: A multicentre study. Nephrol Dial Transplant 1990;5(1):45-53.
D’Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995 Oct;10(10):1874-1884.
Dahl E, Nordal KP, Aksnes L, Halse J. Bone remodeling in predialysis chronic renal failure: How does the choice of index for mineralizing surface influence the interpretation? J Bone Miner Res 1989 Dec;4(6):845-852.
Dahl E, Nordal KP, Attramadal A, Halse J, Flatmark A. Renal osteodystrophy in predialysis patients without stainable bone aluminium. A cross-sectional bone-histomorphometric study. Acta Med Scand 1988;224(2):157-164.
Dahl E, Nordal KP, Attramadal A, Halse J, Flatmark A. Renal osteodystrophy in predialysis patients without stainable bone aluminum. A cross-sectional bone-histomorphometric study. Acta Med Scand 1988;224(2):157-164.
Dahl E, Nordal KP, Halse J, Flatmark A. Pretransplant parathyroidectomy in renal failure: Effects on bone histology and aluminum deposits during dialysis and after kidney transplantation. Scand J Urol Nephrol 1992;26(3):283-288.
Dalal S, Yu AW, Gupta DK, Kar PM, Ing TS, Daugirdas JT. L-lactate high-efficiency hemodialysis: Hemodynamics, blood gas changes, potassium/phosphorus, and symptoms. Kidney Int 1990 Nov;38(5):896-903.
Dalal SP, Ajam M, Gupta DK, Gupta R, Nawab Z, Manahan FJ, Ing TS, Daugirdas JT. L-lactate for high-efficiency hemodialysis: Feasibility studies and a randomized comparison with acetate and bicarbonate. Int J Artif Organs 1989 Oct;12(10):611-617.
Dalen N, Alvestrand A. Bone mineral content in chronic renal failure and after renal transplantation. Clin Nephrol 1973 Nov-Dec;1(6):338-346.
Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993;27(4):447-451.
Davidson JK, Tsakiris D, Briggs JD, Junor BJ. Osteonecrosis and fractures following renal transplantation. Clin Radiol 1985 Jan;36(1):27-35.
Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986 May-Jun;1(3):155-158.
Davison AM, Peacock M, Walker GS, Marshall DH, McLaughlin MS, Robinson PJ. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients. Clin Endocrinol (Oxf) 1977 Dec;7 Suppl:91s-99s.
Dawborn JK, Brown DJ, Douglas MC, Eddey HH, Heale WF, Thomas DP, Xipell JM. Parathyroidectomy in chronic renal failure. Nephron 1983;33(2):100-105.
De Francisco AM, Cassidy MJ, Owen JP, Ellis HA, Farndon JR, Ward MK, Kerr DN. Ectopic calcification. The role of parathyroid hormone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:888-894.
de Francisco AM, Ellis HA, Owen JP, Cassidy MJ, Farndon JR, Ward MK, Kerr DN. Parathyroidectomy in chronic renal failure. Q J M 1985 Jun;55(218):289-315.
de Francisco AM, Riancho JA, Amado JA, del Arco C, Macias JG, Cotorruelo JG, Arias M. Calcium, hyperparathyroidism, and vitamin D metabolism after kidney transplantation. Transplant Proc 1987 Oct;19(5):3721-3723.
de Graaf P, Pauwels EK, Vos PH, Schicht IM, te Velde J, de Graeff J. Observations on computerized quantitative bone scintigraphy in renal osteodystrophy. Eur J Nucl Med 1984;9(9):419-425.
de Graaf P, te Velde J, Pauwels EK, Schicht IM, Kleiverda K, de Graeff J. Increased bone radiotracer uptake in renal osteodystrophy. Clinical evidence of hyperparathyroidism as the major cause. Eur J Nucl Med 1982;7(4):152-154.
De Graaf P, Van Hooff JP, Boekhout M, Achterberg J, Pauwels EK, Kalff MW. Hyperparathyroidism and avascular necrosis of bone after kidney transplantation. A retrospective study of 170 transplant recipients. Neth J Med 1982;25(7):230-236.
De Vecchi A, Rivolta E, Tarantino A, Egidi F, Berardinelli L, Vegeto A, Ponticelli C. Controlled trial of two different methylprednisolone doses in cadaveric renal transplantation. Nephron 1985;41(3):262-266.
de Vernejoul MC, Marchais S, London G, Bielakoff J, Chappuis P, Morieux C, Llach F. Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation. Am J Kidney Dis 1989 Aug;14(2):124-130.
de Vernejoul MC, Marchais S, London G, Morieux C, Bielakoff J, Miravet L. Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney Int 1985 May;27(5):785-791.
Deicher R, Exner M, Cohen G, Haag-Weber M, Horl WH. Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis 2000 Jun;35(6):1117-1126.
Delling G, Luhmann H, Bulla M, Fuchs C, Henning HV, Jansen JL, Kohnle W, Schulz W. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure. Contrib Nephrol 1980;18:105-121.
Delmez JA, Fallon MD, Harter HR, Hruska KA, Slatopolsky E, Teitelbaum SL. Does strict phosphorus control precipitate renal osteomalacia? J Clin Endocrinol Metab 1986 Apr;62(4):747-752.
Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 1996 Jan;49(1):163-167.
Delmonico FL, Wang CA, Rubin NT, Fang LS, Herrin JT, Cosimi AB. Parathyroid surgery in patients with renal failure. Ann Surg 1984 Nov;200(5):644-647.
Demeure MJ, Ugee DC, Wilkes W, Duh QY, Clark OH. Results of surgical treatment for hyperparathyroidism associated with renal disease. Am J Surg 1990 Oct;160(4):337-340.
Denney JD, Sherrard DJ, Nelp WB, Chesnut CH 3d, Baylink DJ. Total body calcium and long-term calcium balance in chronic renal disease. J Lab Clin Med 1973 Aug;82(2):226-240.
DeVeber GA, Oreopoulos DG, Rabinovich S, Lloyd GJ, Meema HE, Beattie BL, Levy D, Husdan H, Rapoport A. Changing pattern of renal osteodystrophy with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1970;16:479-485.
DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, Michelis MF. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 1992 Sep;71(5):284-290.
Diethelm AG, Adams PL, Murad TM, Daniel WW, Whelchel JD, Rutsky EA, Rostand SG. Treatment of secondary hyperparathyroidism in patients with chronic renal failure by total parathyroidectomy and parathyroid autograft. Ann Surg 1981 Jun;193(6):777-793.
DiRaimondo CR, Pollak VE. Beta 2-microglobulin kinetics in maintenance hemodialysis: A comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 1989 May;13(5):390-395.
Djukanovic L, Pejanovic S, Dragojlovic Z, Stosovic M. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3. Ren Fail 1994 Nov;16(6):715-723.
Donckier V, Decoster-Gervy C, Kinnaert P. Long-term results after surgical treatment of renal hyperparathyroidism when fewer than four glands are identified at operation. J Am Coll Surg 1997 Jan;184(1):70-74.
Douthat WG, Acuna Aguerre G, Fernandez Martin JL, Mouzo R, Cannata Andia JB. Treatment of aluminium intoxication: A new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994;9(10):1431-1434.
Douthat WG, Aguerre GA, Martin JLF, Mouzo R, Cannata Andia JB. Treatment of aluminium intoxication: A new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994;9(10):1431-1434.
Coburn J. (UCLA, Dept. of Nephrology, Los Angeles, CA). Personal communication. January 31, 2001.
Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de Vernejoul P, Crosnier J. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1980 Jan 19;1(8160):112-114.
Drusano GL, Standiford HC, Bustamante CJ, et al. Safety and tolerability of multiple doses of imipenem/cilastatin. Clin Pharmacol Ther 1985;37(5):539-543.
Dubost C, Kracht M, Assens P, Sarfati E, Zingraff J, Drueke T. Reoperation for secondary hyperparathyroidism in hemodialysis patients. World J Surg 1986 Aug;10(4):654-660.
Duffy P, Picker RH, Duffield S, Reeve T, Hewlett S. Parathyroid sonography: A useful aid to preoperative localization. J Clin Ultrasound 1980 Apr;8(2):113-116.
Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 1993 Feb;16(2):483-492.
Dumoulin G, Hory B, Nguyen NU, Henriet MT, Bresson C, Regnard J, Saint-Hillier Y. Lack of evidence that cyclosporine treatment impairs calcium-phosphorus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplantation 1995 Jun 27;59(12):1690-1694.
Dunstan CR, Hills E, Norman AW, et al. Treatment of hemodialysis bone disease with 24,25-(OH)D and 1,25-(OH)D alone or in combination. Miner Electrolyte Metab 1985;11(6):358-368.
Duursma SA, Visser WJ, Mees EJ, Njio L. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res 1974;16(2):129-138.
Duursma SA, Visser WJ, Njio L. A quantitative histological study of bone in 30 patients with renal insufficiency. Calcif Tissue Res 1972;9(3):216-225.
Duursma SA, Visser WJ, Raymakers JA, Hart W. A comparative study of radiological and morphometric determinations of bone density in patients with renal osteodystrophy. Folia Med Neerl 1972;15(6):267-270.
Eastwood JB. Quantitative bone histology in 38 patients with advanced renal failure. J Clin Pathol 1982 Feb;35(2):125-134.
Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study [published erratum appears in J Am Soc Nephrol 1997 Mar;8(3):493]. J Am Soc Nephrol 1996 Dec;7(12):2616-2626.
Ei I, Maruyama H, Gejyo F, Okada M, Aoyagi R, Sato T, Ohara K, Tanizawa T, Takahashi HE, Arakawa M. Histomorphometric analysis of aplastic bone disease in chronic renal failure at initiation of haemodialysis: Relation to aluminum and parathormone. Nephrology 1998;4(3):129-136.
Eke FU, Winterborn MH, Robertson PW. Detection of early renal osteodystrophy. Child Nephrol Urol 1988-89;9(1-2):33-37.
el-Reshaid K, el-Reshaid W, Sugathan T, al-Mohannadi S, Sivanandan R. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997;17(6):505-510.
Ellis HA, Peart KM. Azotaemic renal osteodystrophy: A quantitative study on iliac bone. J Clin Pathol 1973 Feb;26(2):83-101.
Elmstedt E. Avascular bone necrosis in the renal transplant patient: A discriminant analysis of 144 cases. Clin Orthop 1981 Jul-Aug;(158):149-157.
Elmstedt E. Incidence of skeletal complications in renal graft recipients. Effect of changes in pharmacotherapy. Acta Orthop Scand 1982 Dec;53(6):853-856.
Elvin A. Therapy evaluation and diagnostic accuracy in neuroendocrine tumours: Assessment of radiological methods. Acta Radiol Suppl 1993;390:1-25.
Emiliani G, Riegler P, Corradini R, Huber W, Fusaroli M. Calcium-phosphorus metabolism after successful kidney transplantation: comparison between patients treated with conventional immunosuppressive therapy and cyclosporin A. Dev Toxicol Environ Sci 1986;14:157-162.
Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991 May;17(5):544-550.
Escobedo EM, Hunter JC, Zink-Brody GC, Andress DL. Magnetic resonance imaging of dialysis-related amyloidosis of the shoulder and hip. Skeletal Radiol 1996 Jan;25(1):41-48.
Esselstyn CB Jr, Popowniak KL. Parathyroid surgery in the treatment of renal osteodystrophy and tertiary hyperparathyroidism. Surg Clin North Am 1971 Oct;51(5):1211-1217.
Abbott Laboratories. Essentials in osteo dynamics manual [website]. Abbott Park, IL, Abbott Laboratories, 2000. [cited February 28, 2000]. [62p]
Eu commission approves Visudyne for the treatment of wet amd in the European Union [press release online]. Atlanta, GA, QLT Inc, July 28, 2000 [cited August 1, 2000] [7]. Available: http://www.qltinc.com.
Evans RA, Flynn J, Dunstan CR, George CR. Quantitative bone histology in end-stage renal failure. Prog Biochem Pharmacol 1980;17:236-241.
Evans RA, Flynn J, Dunstan CR, George CR, McDonnell GD. Bone metabolism in chronic renal failure. Miner Electrolyte Metab 1982 Apr;7(4):207-218.
Fabretti F, Calabrese V, Fornasari V, Poletti I. Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol 1991 Jul;105(7):562-567.
Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 1995 Nov;57(5):329-335.
Falbo SE, Sundaram M, Ballal S, Domoto D, Martin K. Clinical significance of erosive azotemic osteodystrophy: A prospective masked study. Skeletal Radiol 1999 Feb;28(2):86-89.
Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000 Feb;57(2):684-690.
Farrington K, Varghese Z, Baillod RA, Fernando ON, Moorhead JF. Hypophosphataemia after parathyroidectomy in chronic renal failure. Br Med J (Clin Res Ed) 1982 Mar 20;284(6319):856-858.
Fassier F, St-Pierre M, Robitaille P. Renal osteodystrophy in children: correlation between aetiology of the renal disease and the frequency of bone and articular lesions. Int Orthop 1993;17(4):269-271.
Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 1986 Jun;107(6):481-487.
Felsenfeld AJ, Gutman RA, Drezner M, Llach F. Hypophosphatemia in long-term renal transplant recipients: Effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986;12(5-6):333-341.
Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM, Wells SA. Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient. Miner Electrolyte Metab 1984;10(3):166-172.
Felsenfeld AJ, Harrelson JM, Gutman RA. A quantitative histomorphometric comparison of 40 micron thick Paragon sections with 5 micron thick Goldner sections in the study of undecalcified bone. Calcif Tissue Int 1982 May;34(3):232-238.
Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993;13(4):296-301.
Feriani M, Kirchgessner J, La Greca G, Passlick- Deetjen J, Becker H, Bohler J, Brown CB, Buoncristiani U, Di Paolo N, Gahl GM, Gotloib L, Hylander B, Lameire N, Montenegro J, Pedersen FB, et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998;54(5):1731-1738.
Fernandez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol 1997 Oct;8(10):1546-1552.
Fernandez-Reyes MJ, Auxiliadora Najo M, Robles P, Selgas R, Oliver J, Del Peso G, Garcia G, Jimenez C, Garcia-Gallego F. Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. Nephrol Dial Transplant 1995;10(11):2090-2095.
Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, Domene H, Jasper H. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 2000 Jul;14(7):682-688.
Finch T, Jacobs JK. Indications for parathyroidectomy in patients with chronic renal failure. Am Surg 1974 Jan;40(1):40-44.
Fischer ER, Harris DC. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993 Oct;40(4):216-220.
Fletcher S, Jones RG, Rayner HC, Harnden P, Hordon LD, Aaron JE, Oldroyd B, Brownjohn AM, Turney JH, Smith MA. Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997;75(4):412-419.
Fletcher S, Kanagasundaram NS, Rayner HC, Irving HC, Fowler RC, Brownjohn AM, Turney JH, Will EJ, Davison AM. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant 1998 Dec;13(12):3111-3117.
Floege J. Beta-2-microglobulin derived amyloid and acquired cystic kidney disease, in Johnson RJ, Feehally J (eds): Principles of Nephrology. London, UK, Mosby International, 2000, pp 73.1-73.8.
Floege J. Diagnostic approaches to AB-amyloidosis. Blood Purif 1991;9(2):63-69.
Floege J, Burchert W, Brandis A, Gielow P, Nonnast-Daniel B, Spindler E, Hundeshagen H, Shaldon S, Koch KM. Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-beta 2-microglobulin. Kidney Int 1990 Dec;38(6):1169-1176.
Floege J, Granolleras C, Merscher S, Eisenbach GM, Deschodt G, Colton CK, Shaldon S, Koch KM. Is the rise in plasma beta-2-microglobulin seen during hemodialysis meaningful? Nephron 1989;51(1):6-12.
Floege J, Schaeffer J, Koch KM. Diagnosis of beta-2-microglobulin associated amyloidosis by scintigraphy. Top Rev Rheum Disord 1994;61(9 Suppl):39S-42S.
Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000 Sep;54(3):218-226.
Foret M, Renversez JC, Meftahi H, Kuentz F, Milongo R, Hachache T, Vallin J, Dechelette E, Cordonnier D. How far can plasmatic levels of beta-2-microglobulin in hemodialysis be relied upon? Contrib Nephrol 1988;62:54-59.
Forget D, Caranhac G, Quillot MJ, Besnier MO. Compliance with very low protein diet and ketoanalogues in chronic renal failure. The French Multicentric Trial IRCCA. Contrib Nephrol 1990;81:79-86.
Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral anular calcification in chronic renal failure. Chest 1984 Mar;85(3):367-371.
Fournier A, Fohrer P, Leflon P, Moriniere P, Tolani M, Lambrey G, Demontis R, Sebert JL, Van Devyver F, Debroe M. The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:371-376.
Franck H, Keck E, Issa S, Kruskemper HL, von Lilienfeld-Toal H. Serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin in chronic renal failure. Exp Clin Endocrinol 1988 May;91(2):202-206.
Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 1998 Feb 21;3(1-2):81-88.
Franklin SS, Gordon A, Kleeman CR, Maxwell MH. Use of a balanced low-protein diet in chronic renal failure. JAMA 1967 Nov 6;202(6):477-484.
Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000 Sep;36(3):550-561.
Freaney R, McKenna MJ, Casey O, Towers RP, Muldowney FP. Prospective application of a diagnostic index for metabolic bone disease. Ir Med J 1986 Apr;79(4):96-99.
Friberg O, Nurminen M, Korhonen K, Soininen E, Manttari T. Accuracy and precision of clinical estimation of leg length inequality and lumbar scoliosis: comparison of clinical and radiological measurements. Int Disabil Stud 1988;10(2):49-53.
Frohling PT, Kokot F, Schmicker R, Kaschube I, Lindenau K, Vetter K. Influence of keto acids on serum parathyroid hormone levels in patients with chronic renal failure. Clin Nephrol 1983 Oct;20(4):212-215.
Frohling PT, Kokot F, Vetter K, Hohmann WD, Werner G, Grossmann I, Schmicker R, Lindenau K. Treatment of renal osteodystrophy in advanced renal failure during predialysis time. Contrib Nephrol 1984;37:62-65.
Frohling PT, Schmicker R, Kokot F, Vetter K, Kaschube J, Gotz KH, Jacopian M, Lindenau K. Influence of phosphate restriction, keto-acids and vitamin D on the progression of chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:561-566.
Frohling PT, Schmicker R, Vetter K, Kaschube I, Gotz KH, Jacopian M, Klinkman H. Conservative treatment with ketoacid and amino acid supplemented low-protein diets in chronic renal failure. Am J Clin Nutr 1980 Jul;33(7):1667-1672.
Fujimoto Y, Obara T, Ito Y, Kodama T, Nishi T. Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure: Reevaluation of indications for parathyroidectomy. Endocrinol Jpn 1985 Dec;32(6):863-874.
Fujisaki T, Hida M, Hiraga S, Osamura RY. Cellular proliferation and secretion in secondary hyperparathyroidism during renal failure. Nephron 1997;77(1):68-75.
Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 Sep;92(3):1436-1443.
Fuss M, De Backer M, Brauman J, Nijs-Dewolf N, Manderlier T, Brauman H, Corvilain J. Parathyroid hormone plasma level in untreated chronic renal failure and in hemodialyzed patients. Nephron 1976;17(2):144-154.
Gabay C, Ruedin P, Slosman D, Bonjour JP, Leski M, Rizzoli R. Bone mineral density in patients with end-stage renal failure. Am J Nephrol 1993;13(2):115-123.
Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K. Pulse oral versus pulse intraperitoneal calcitriol: A comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 2000;16:303-307.
Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drueke TB. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992 Oct;3(4):1008-1017.
Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992 Nov;42(5):1191-1198.
Gao H, Lew SQ, Bosch JP. Moderate metabolic acidosis and its effects on serum parameters in hemodialysis patients. Nephron 2000 Oct;86(2):135-138.
Gasparri G, Camandona M, Jeantet A, Nano M, Desimone M, Bronda M, Deipoli M. Results after 223 parathyroidectomies for secondary hyperparathyroidism. Acta Chir Austriaca 1996;28(Suppl 124):32-34.
Gaucher A, Kessler M, Netter P, Azoulay E, Pere P, Mur JM. Dialysis arthropathy: the effect of age [letter]. J Rheumatol 1988 Dec;15(12):1880-1881. [letter]
Gaylin DS, Held PJ, Port FK, Hunsicker LG, Wolfe RA, Kahan BD, Jones CA, Agodoa LY. The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA 1993 Feb 3;269(5):603-608.
Geis WP, Popovtzer MM, Corman JL, Halgrimson CG, Groth CG, Starzi TE. The diagnosis and treatment of hyperparathyroidism after renal homotransplantation. Surg Gynecol Obstet 1973 Dec;137(6):997-1010.
Gejyo F, Homma N, Maruyama H, Arakawa M. Beta 2-microglobulin-related amyloidosis in patients receiving chronic hemodialysis. Contrib Nephrol 1988;68:263-269.
Gejyo F, Homma N, Saito H, Arakawa M. Carpal tunnel syndrome and beta-2 microglobulin amyloidosis: Histological and biochemical aspects, in Gejyo F, Brancaccio D, Bardin T, (eds): Dialysis Amyloidosis. Milan, Italy, Wichtig Editore, 1989, pp 35-56.
Gejyo F, Homma N, Suzuki Y, Arakawa M. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis [letter]. N Engl J Med 1986 Feb 27;314(9):585-586. [letter]
Gentile MG, Manna GM, Ferrario L, D’Amico G. Preliminary experience on dietary management of chronic renal failure. Contrib Nephrol 1986;53:102-108.
Genuth SM, Sherwood LM, Vertes V, Leonards JR. Plasma parathormone, calcium and phosphorus in patients with renal osteodystrophy undergoing chronic hemodialysis. J Clin Endocrinol Metab 1970 Jan;30(1):15-23.
Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996 Dec;11(12):2430-2438.
Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 1999 Jun;55(6):2169-2177.
Ghods AJ, Arghani H, Ghadiri G. Serum erythropoietin levels after renal transplantation with various graft outcomes. Transplant Proc 1995 Oct;27(5):2577-2578.
Giangrande A, Cant A, Solbiati L, Ravetto C. Ultrasonically guided fine-needle alcohol injection as an adjunct to medical treatment in second hyperparathyroidism. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1984;21:895-901.
Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992;7(5):412-421.
Giovannetti S. The compliance with supplemented diet by chronic uremics and their nutritional status. Infusionsther Klin Ernahr 1987 Oct;14(Suppl 5):4-7.
Goggin MJ, Black DA, Wells CP, Collins RE, Coakley AJ, Nunan TO, Wolfe JH, Gaunt JI, Croft DN, Young AE. Thallium-201 and technetium-99m subtraction scanning of the parathyroid glands in patients with hyperparathyroidism due to renal osteodystrophy. Contrib Nephrol 1987;56:196-199.
Gldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77(1):37-43.
Goldstein DA, Malluche HH, Massry SG. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol 1980;18:42-54.
Goldstein S, Winston E, Chung TJ, et al. Chronic arthropathy in long-term hemodialysis. Am J Med 1985;78(1):82-86.
Gonzalez T, Cruz A, Balsa A, Jimenez C, Selgas R, Miguel JL, Gijon J. Erosive azotemic osteoarthropathy of the hands in chronic ambulatory peritoneal dialysis and hemodialysis. Clin Exp Rheumatol 1997 Jul-Aug;15(4):367-371.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary artery calcification in young adults with end state renanl disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-1483.
Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994 Oct;46(4):1160-1166.
Gosling P, Robinson BH, Sammons HG. Changes in protein-bound calcium in the serum of haemodialysis patients. Clin Sci Mol Med Suppl 1975 Jun;48(6):521-528.
Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggera WF. Renal phosphate wasting after successful kidney transplantation: 1-alpha vitamin D therapy in patients with normal parathyroid gland activity. Nephron 1981;28(6):285-288.
Greene SV, Falciglia G, Rademacher R. Relationship between serum phosphorus levels and various outcome measures in adult hemodialysis patients. J Ren Nutr 1998 Apr;8(2):77-82.
Grekas DM, Ellis HA, Ward MK, Martin AM, Parkinson I, Kerr DN. Bone disease in long-term hemodialysis patients with low dialysate aluminium. Uremia Invest 1984;8(1):9-15.
Gretz N, Meisinger E, Strauch M. Influence of diet and underlying renal disease on the rate of progression of chronic renal failure. Infusionsther Klin Ernahr 1987;14(Suppl 5):21-25.
Grotz W, Mundinger A, Gugel B, Exner V, Reichelt A, Schollmeyer P. Missing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant Proc 1994 Oct;26(5):2652-2653.
Grotz W, Rump JA, Niessen A, Schmidt-Gayk H, Schollmeyer P. Treatment of bone pain after kidney transplantation. Transplant Proc 1998 Aug;30(5):2114-2116.
Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation 1994;58(8):912-915.
Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995;10(11):2096-2100.
Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998 Oct 27;66(8):1004-1008.
Growth failure in children with renal diseases. A clinical trial in pediatric nephrology: Growth Failure in Renal Diseases (GFRD) Study. J Pediatr 1990 Feb;116(2):S1-S62.
Gurudev KC, Pathak V, Prabhakar KS, Bhaskar S, Prakash KC, Prabhakaran, Mani MK. Short term study on relative merits of acetate and bicarbonate dialysis. J Assoc Physicians India 1991 Dec;39(12):921-924.
Gyarmati J, Locsey L, Gyarmati J Jr, Barnak G, Kakuk G, Vargha G. The value of roentgenological and serological investigations in the detection of bone alterations caused by chronic renal insufficiency. Radiol Diagn (Berl) 1979;20(5):738-478.
Haajanen J, Saarinen O, Kuhlback B, et al. Aseptic necrosis of the femoral head following renal transplantation. Scand J Urol Nephrol 1985;19(3):221-226.
Haajanen J, Saarinen O, Laasonen L, Kuhlback B, Edgren J, Slatis P. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients. Transplant Proc 1984 Oct;16(5):1316-1319.
Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988 Mar;11(3):238-247.
Hakim RM, Pontzer MA, Tilton D, Lazarus JM, Gottlieb MN. Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Kidney Int 1985 Sep;28(3):535-540.
Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF 3rd. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996 Mar;7(3):472-478.
Hamdy NA, Boletis J, Charlesworth D, Kanis JA, Brown CB. Low calcium dialysate increases the tolerance to vitamin D in peritoneal dialysis. Contrib Nephrol 1991;89:190-198.
Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995 Feb 11;310(6976):358-363.
Hamdy NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, Kanis JA. Serum type I procollagen peptide: A non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994;9(5):511-516.
Hampl H, Steinmuller T, Frohling P, Naoum C, Leder K, Stabell U, Schnoy N, Jehle PM. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999 May-Jun;25(3):161-170.
Hampl H, Steinmuller T, Stabell U, Klingenberg HJ, Schnoy N, Neuhaus P. Recurrent hyperparathyroidism after total parathyroidectomy and autotransplantation in patients with long-term hemodialysis. Miner Electrolyte Metab 1991;17(4):256-260.
Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, NY, Russell Sage Foundation, 1994. 573 p.
Hargrove GM, Pasieka JL, Hanley DA, Murphy MB. Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end- stage renal disease. Am J Nephrol 1999;19(5):559-564.
Harrison JE, McNeill KG, Meema HE, Oreopoulos D, Rabinovich S, Fenton S, Wilson DR. Partial body calcium measurements on patients with renal failure. Metabolism 1977 Mar;26(3):255-265.
Hart W, Duursma SA, Visser WJ, Njio LK. The hydroxyproline content of plasma of patients with impaired renal function. Clin Nephrol 1975;4(3):104-108.
Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull 1995 Jan;117(1):167-178.
Hauglustaine D, Waer M, Michielsen P, Goebels J, Vandeputte M. Haemodialysis membranes, serum beta 2-microglobulin, and dialysis amyloidosis [letter]. Lancet 1986 May 24;1(8491):1211-1212.
Hayes JF, Gross GF, Schuman ES. Surgical management of renal hyperparathyroidism in the dialysis patient. Am J Surg 1982 May;143(5):569-571.
Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000 Oct;14(5):457-463.
Heaf JG, Podenphant J, Andersen JR. Bone aluminium deposition in maintenance dialysis patients treated with aluminium-free dialysate: Role of aluminium hydroxide consumption. Nephron 1986;42(3):210-216.
Hecking E, Andrzejewski L, Prellwitz W, Opferkuch W, Muller D, Port FK. A controlled study of supplementation with essential amino acids and alpha-keto acids in the conservative management of patients with chronic renal failure. Z Ernahrungswiss 1982 Dec;21(4):299-311.
Hedges LV, Olkin I. Statistical methods for meta-analysis. Boston, MA, Academic Press, Inc, 1985. 369 p.
Heerfordt J, Olgaard K, Madsen S, Vistisen L, Jensen H, Lookkegaard H, Brix E. Osteoscintigraphic changes in kidney-transplanted patients. Nephron 1978;21(2):86-94.
Heidland A, Kult J. Long-term effects of essential amino acids supplementation in patients on regular dialysis treatment. Clin Nephrol 1975 Jun;3(6):234-239.
Hellman P, Backman U, Danielson BG, Akerstrom G, Rastad J, Wide L, Ljunghall S. Values of intact serum parathyroid hormone in different stages of renal insufficiency. Scand J Urol Nephrol 1991;25(3):227-232.
Hely D, Fennell RS 3d, Petty W, Hudson T, Richard GA. Osteonecrosis of the femoral head and condyle in the post transplantation courses of children and adolescents. Int J Pediatr Nephrol 1982 Dec;3(4):297-303.
Hemmeloff Andersen KE, Bengsgaard Pedersen F, Horder M. An assessment of dialysis-associated osteodystrophy in long-term peritoneal dialysis. Nephron 1982;30(4):328-332.
Henderson RG, Russell RG, Earnshaw MJ, Ledingham JG, Oliver DO, Woods CG. Loss of metacarpal and iliac bone in chronic renal failure: influence of haemodialysis, parathyroid activity, type of renal disease, physical activity and heparin consumption. Clin Sci (Colch) 1979 Apr;56(4):317-324.
Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin LJ. High sodium bicarbonate and acetate hemodialysis: double-blind crossover comparison of hemodynamic and ventilatory effects. Kidney Int 1983 Aug;24(2):240-245.
Henry JF, Denizot A, Audiffret J, France G. Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients. World J Surg 1990 May-Jun;14(3):303-306; discussion 307.
Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ. Aplastic osteodystrophy without aluminum: The role of ‘suppressed’ parathyroid function. Kidney Int 1993 Oct;44(4):860-866.
Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW. Aluminum removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine. Kidney Int 1986 Dec;30(6):944-948.
Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994;9(5):517-523.
Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch K-M, Weber U, Horl W, Haas-Worle A, Kuhn K, Bierther B, Schneider P. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 1994;67(1):48-53.
Herselman MG, Albertse EC, Lombard CJ, Swanepoel CR, Hough FS. Supplemented low-protein diets—Are they superior in chronic renal failure? S Afr Med J 1995 May;85(5):361-365.
Higgins RM, Richardson AJ, Ratcliffe PJ, Woods CG, Oliver DO, Morris PJ. Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J M 1991 Apr;79(288):323-332.
Hindie E, Urena P, Jeanguillaume C, Melliere D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet 1999 Jun 26;353(9171):2200-2204.
Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999 Dec;56(6):2040-2047.
Hodson EM, Evans RA, Dunstan CR, Hills E, Wong SY, Rosenberg AR, Roy LP. Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Clin Nephrol 1985 Oct;24(4):192-200.
Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, lmaden Y, Felsenfeld AJ. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 2000 May;15(5):927-935.
Holman AJ, Gardner GC, Richardson ML, Simkin PA. Quantitative magnetic resonance imaging predicts clinical outcome of core decompression for osteonecrosis of the femoral head. J Rheumatol 1995 Oct;22(10):1929-1933.
Homma N, Gejyo F, Kobayashi H, Saito H, Sakai S, Suzuki M, Hirasawa Y, Arakawa M. Cystic radiolucencies of carpal bones, distal radius and ulna as a marker for dialysis-associated amyloid osteoarthropathy. Nephron 1992;62(1):6-12.
Honda K, Hara M, Ogura Y, Nihei H, Mimura N. Beta 2-microglobulin amyloidosis in hemodialysis patients. An autopsy study of intervertebral disks and posterior longitudinal ligaments. Acta Pathol Jpn 1990 Nov;40(11):820-826.
Hosking DJ, Chamberlain MJ. Calcium balance in chronic renal failure. A study using in vivo neutron activation analysis. Q J M 1973 Jul;42(167):467-479.
Hosokawa S, Yoshida O. Removal of silicon, aluminum and beta 2-microglobulin in chronic haemodialysis patients. Int Urol Nephrol 1991;23(3):281-284.
Howard RJ, Pfaff WW. Parathyroidectomy in patients with chronic renal failure. Am J Surg 1998 Apr;175(4):302-304.
Hulter HN, Peterson JC. Acid-base homeostasis during chronic PTH excess in humans. Kidney Int 1985 Aug;28(2):187-192.
Huraib S, Souqqiyeh MZ, Aswad S, al-Swailem AR. Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia. Nephrol Dial Transplant 1993;8(7):603-608.
Hurst NP, van den Berg R, Disney A, Alcock M, Albertyn L, Green M, Pascoe V. ‘Dialysis related arthropathy’: A survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis. Ann Rheum Dis 1989 May;48(5):409-420.
Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992;7(12):1219-1225.
Hutchison AJ, Freemont AJ, Lumb GA, Gokal R. Renal osteodystrophy in CAPD. Adv Perit Dial 1991;7:237-239.
Hutchison AJ, Merchant M, Boulton HF, Hinchcliffe R, Gokal R. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Perit Dial Int 1993;13(3):219-223.
Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993 Nov;44(5):1071-1077.
Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 1994;14(1):19-29.
Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Weil R 3d. Calcification in end-stage kidneys. Am J Med 1981 Jul;71(1):33-37.
Ibels LS, Alfrey AC, Huffer WE, Weil R 3d. Aseptic necrosis of bone following renal transplantation: Experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978 Jan;57(1):25-45.
Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989 Dec 28;321(26):1773-1777.
Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J Clin Endocrinol Metab 1998 Nov;83(11):3860-3866.
Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000 JAN;57(1):282-292.
Ingham JP, Stewart JH, Posen S. Quantitative skeletal histology in untreated end-stage renal failure. Br Med J 1973 Jun 30;2(869):745-748.
Ishibashi M, Nishida H, Hiromatsu Y, Kojima K, Tabuchi E, Hayabuchi N. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands . J Nucl Med 1998 Feb;39(2):320-324.
Ishibashi M, Nishida H, Okuda S, Suekane S, Hayabuchi N. Localization of parathyroid glands in hemodialysis patients using Tc-99m sestamibi imaging. Nephron 1998;78(1):48-53.
Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999 Mar;55(3):1019-1027.
Ito M, Ito M, Hayashi K, Noguchi M, Kitamori H. Evaluation of spinal bone changes in patients with chronic renal failure by CT and MR imaging with pathologic correlation. Acta Radiol 1994 May;35(3):291-295.
Ittel TH, Schafer C, Schmitt H, Gladziwa U, Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 1991 Jan 22;69(2):59-67.
Coburn J. (UCLA Medical Center). Personal communication. December 22, 2000.
Jacobs JW, Blaauw AA, Dijkmans BA, Van Riel PL, Bijlsma JW. Pharmacotherapy of patients with (early) rheumatoid arthritis. Ned Tijdschr Geneeskd 2000;144(5):211-216.
Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de Strihou C. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 1997 Jun;51(6):1928-1932.
Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C. Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol Dial Transplant 1993;8(10):1104-1109.
Janssen MJ, van Boven WP. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Pharm World Sci 1996 Oct;18(5):187-191.
Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996 Feb;45(2):111-119.
Jarava C, Armas JR, Salgueira M, Palma A. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996;11 Suppl 3:43-46.
Jeanguillaume C, Urena P, Hindie E, Prieur P, Petrover M, Menoyo-Calonge V, Janin A, Chiappini-Briffa D, Melliere D, Boulahdour H, Galle P. Secondary hyperparathyroidism: Detection with I-123-Tc-99m-Sestamibi subtraction scintigraphy versus US. Radiology 1998 Apr;207(1):207-213.
Jenkins DA, Gouldesbrough D, Smith GD, Cowie JF, Winney RJ. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant 1989;4(1):51-56.
Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, Gammelgaard B, Pedersen EB. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephrol Dial Transplant 1991;6(2):98-104.
Joffe P, Heaf JG, Jensen C. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis? Miner Electrolyte Metab 1996;22(4):224-233.
Johnson DW, Rigby RJ, McIntyre HD, Brown A, Freeman J. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Nephrol Dial Transplant 1996 Jan;11(1):88-93.
Johnson WJ, McCarthy JT, van Heerden JA, Sterioff S, Grant CS, Kao PC. Results of subtotal parathyroidectomy in hemodialysis patients. Am J Med 1988 Jan;84(1):23-32.
Jorge C, Gil C, Possante M, Catarino MC, Cruz A, Andrade R, Teixeira R, Santos N, Ferreira A. Use of a desferrioxamine ‘microdose’ to chelate aluminum in hemodialysis patients. Clin Nephrol 1999;52(5):335-336.
Jureidini KF, Hogg RJ, van Renen MJ, Southwood TR, Henning PH, Cobiac L, Daniels L, Harris S. Evaluation of long-term aggressive dietary management of chronic renal failure in children. Pediatr Nephrol 1990 Jan;4(1):1-10.
Juttmann JR, Birkenhager-Frenkel DH, Visser TJ, van Krimpen C, Birkenhager JC. Follow-up of long-term treatment of predialysis renal bone disease with 1-alpha-hydroxy-derivatives of vitamin D. J Steroid Biochem 1983 Jul;19(1B):511-516.
Juttmann JR, Hagenouw-Taal JC, Lameyer LD, Ruis AM, Birkenhager JC. A longitudinal study of bone-mineral content and intestinal calcium absorption in patients with chronic renal failure. Metabolism 1979 Nov;28(11):1114-1121.
Kachel HG, Altmeyer P, Baldamus CA, Koch KM. Deposition of an amyloid-like substance as a possible complication of regular dialysis treatment. Contrib Nephrol 1983;36:127-132.
Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999 Jun;33(6):1091-1099.
Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients. Biomed Pharmacother 2000;54(Suppl 1):60S-65S.
Kampf D, Fischer HC, Kessel M. Efficacy of an unselected protein diet (25 g) with minor oral supply of essential amino acids and keto analogues compared with a selective protein diet (40 g) in chronic renal failure. Am J Clin Nutr 1980 Jul;33(7):1673-1677.
Kamphuis AGA, Geerlings W, Hazenberg BPC, Thijn CJP. Annual evaluation of hip joints and hands for radiographic signs of AßM-amyloidosis in long-term hemodialysis patients. Skeletal Radiol 1994;23(6):421-427.
Kancir CB, Wanscher M, Petersen PH. Ionized and total calcium variations induced by haemodialysis. Nephron 1988;48(4):319-323.
Kanis JA, Earnshaw M, Henderson RG, Heynen G, Ledingham JG, Naik RB, Oliver DO, Russell RG, Smith R, Wilkinson RH, Woods CG. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Clin Endocrinol (Oxf) 1977 Dec;7 Suppl:45s-50s.
Karantanas AH, Kalef-Ezra JA, Sferopoulos G, Siamopoulos KC. Quantitative computed tomography for spinal bone mineral measurements in chronic renal failure. Br J Radiol 1996 Feb;69(818):132-136.
Karkoszka H, Chudek J, Strzelczyk P, Wiecek A, Schmidt-Gayk H, Ritz E, Kokot F. Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients? Nephrol Dial Transplant 1998 Aug;13(8):2077-2080.
Karsenty G, Vigneron N, Jorgetti V, Fauchet M, Zingraff J, Drueke T, Cournot-Witmer G. Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy. Kidney Int 1986 May;29(5):1058-1065.
Kasiske BL, London W, Ellison MD. Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. J Am Soc Nephrol 1998 Nov;9(11):2142-2147.
Katagiri M, Fukunaga M, Ohtawa T, Harada T, Henry JF. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: Evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I p(TRUNC). World J Surg 1996;20(7):753-757.
Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis 1997 Dec;30(6):809-813.
Katz AD, Kaplan L. Parathyroidectomy for hyperplasia in renal disease. Arch Surg 1973 Jul;107(1):51-55.
Katz AI, Hampers CL, Merrill JP. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine (Baltimore) 1969 Sep;48(5):333-374.
Katz AI, Hampers CL, Wilson RE, Bernstein DS, Wachman A, Merrill JP. The place of subtotal parathyroidectomy in the management of patients with chronic renal failure. Trans Am Soc Artif Intern Organs 1968;14:376-384.
Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, Sherrard DJ. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999 Oct;34(4):688-693.
Kawanishi H, Tsuchiya T, Namba S, Takahashi N, Toyota T, Fukuma K, Kawai T. Clinical application of low calcium peritoneal dialysate. ASAIO Trans 1991 Jul-Sep;37(3):M404-M406.
Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF Jr. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 1992 Aug;35(8):926-932.
Kaye M. Long-term studies using a calcium-free dialysate. Clin Nephrol 1993;40(4):221-224.
Kaye M, D’Amour P, Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int 1989 Jun;35(6):1390-1399.
Kaye M, Henderson J. Direct functional assessment of human osteoblasts by radioautography: methodology and application in end stage renal disease. Clin Invest Med 1988 Jun;11(3):224-233.
Kaye M, Rosenthall L, Hill RO, Tabah RJ. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993 Apr;39(4):192-197.
Kaye M, Silverman M. Calcium metabolism in chronic renal failure. J Lab Clin Med 1965 Oct;66(4):535-548.
Kaye M, Turner M, Ardila M, Wiegmann T, Hodsman A. Aluminum and phosphate. Kidney Int Suppl 1988 Mar;24:S172-S174.
Kerby JD, Rue LW, Blair H, Hudson S, Sellers MT, Diethelm AG. Operative treatment of tertiary hyperparathyroidism: a single-center experience. Ann Surg 1998 Jun;227(6):878-886.
Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A. Dialysis-associated arthropathy: A multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 1992 Mar;31(3):157-162.
Kessler M, Netter P, Gaucher A. Dialysis membranes and dialysis-associated arthropathy. Rev Rhum Engl Ed 1994;61(9 Suppl):71S-74S.
Kessler M, Netter P, Maheut H, Wolf C, Prenat E, Huu TC, Gaucher A. Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy [letter]. Lancet 1991 May 4;337(8749):1092-1093.
Khajehdehi P, Ali M, Al-Gebory F, Henry G, Bastani B. The effects of parathyroidectomy on nutritional and biochemical status of hemodialysis patients with severe secondary hyperparathyroidism. J Ren Nutr 1999 Oct;9(4):186-191.
Kim HC, Cheigh JS, David DS, Stubenbord W, Sullivan J, Rubin AL, Stenzel KH. Long term results of subtotal parathyroidectomy in patients with end- stage renal disease. Am Surg 1994 Sep;60(9):641-649.
Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 1998 Jul;71:S238-S241.
Kinnaert P, Nagy N, Decoster-Gervy C, De Pauw L, Salmon I, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg 2000 Nov;24(11):1391-1395.
Kinnaert P, Salmon I, Decoster-Gervy C, Vienne A, De Pauw L, Hooghe L, Tielemans C. Long-term results of subcutaneous parathyroid grafts in uremic patients. Arch Surg 2000 Feb;135(2):186-190.
Kinnaert P, Tielemans C, Dhaene M, Decoster-Gervy C. Evaluation of surgical treatment of renal hyperparathyroidism by measuring intact parathormone blood levels on first postoperative day. World J Surg 1998 Jul;22(7):695-699.
Kist-van Holthe tot Echten JE, Nauta J, Boerma GJ, Hop WC, Noordzij CM, Wolff ED. Protein restriction affects fat intake and serum lipids in children with chronic renal failure. Miner Electrolyte Metab 1992;18(2-5):207-211.
Kist-van Holthe tot Echten JE, Nauta J, Hop WC, de Jong MC, Reitsma-Bierens WC, Ploos van Amstel SL, van Acker KJ, Noordzij CM, Wolff ED. Protein restriction in chronic renal failure. Arch Dis Child 1993 Mar;68(3):371-375.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994 Mar 31;330(13):877-884.
Klaus G, Mehls O, Hinderer J, Ritz E. Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? [letter]. Lancet 1991 Mar 30;337(8744):800-801.
Klinkmann H, Buscaroli A, Stefoni S. ß-Microglobulin and low-flux synthetic dialyzers. Artif Organs 1998;22(7):585-590.
Kobayashi S, Miyakawa M, Kasuga Y, Yokozawa T, Senga O, Sugenoya A, Iida F. Parathyroid imaging: Comparison of 201Tl-99mTc subtraction scintigraphy, computed tomography and ultrasonography. Jpn J Surg 1987 Jan;17(1):9-13.
Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997 Oct;52(4):1096-1101.
Kohlmeier M, Saupe J, Schaefer K, Asmus G. Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 1998 Mar;62(3):278-281.
Koonsman M, Hughes K, Dickerman R, Brinker K, Dunn E. Parathyroidectomy in chronic renal failure. Am J Surg 1994 Dec;168(6):631-634; discussion 634-635.
Kopple JD, Berg R, Houser H, Steinman TI, Teschan P. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989 Nov;27:S184-S194.
Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 1997 Sep;52(3):778-791.
Korzets Z, Magen H, Kraus L, Bernheim J, Bernheim J. Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism—Should it be abandoned? Nephrol Dial Transplant 1987;2(5):341-346.
Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 1997 Jan-Mar;82(1):85-86.
Kraut JA, Shinaberger JH, Singer FR, Sherrard DJ, Saxton J, Miller JH, Kurokawa K, Coburn JW. Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. Kidney Int 1983 May;23(5):725-730.
Kriegshauser JC, Swee RG, McCarthy JT, Hauser MF. Aluminum toxicity in patients undergoing dialysis: Radiographic findings and prediction of bone biopsy results. Radiology 1987;164(2):399-403.
Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996;16(6):484-488.
Kuhlback B, Sivula A, Kock B, Kahri A, Wallenius M. Secondary hyperparathyroidism and parathyroidectomy in terminal chronic renal failure. Scand J Urol Nephrol Suppl 1977;(42):140-143.
Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998 Jan;53(1):205-211.
Kuizon BD, Salusky IB. Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 1998;24(4):290-295.
Kuntz D, Maziere B, Sebert JL, Moriniere P, Meunier PJ, Duquesnoy N, Fournier A. Advantage of hand bone calcium content measurement by local neutron activation analysis for following up hemodialysis patients. Nephron 1983;34(4):228-233.
Kurer MH, Baillod RA, Madgwick JC. Musculoskeletal manifestations of amyloidosis. A review of 83 patients on haemodialysis for at least 10 years. J Bone Joint Surg Br 1991 Mar;73(2):271-276.
Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994 Sep;46(3):855-861.
Kusec V, Smalcelj R, Cvijetic S, Rozman B, Skreb F. Determinants of reduced bone mineral density and increased bone turnover after kidney transplantation: cross-sectional study. Croat Med J 2000 Dec 15;41(4):396-400.
Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol 1977 Feb;86(2):403-424.
La Greca G, Feriani M, Bragantini L, et al. Effects of acetate and bicarbonate dialysate on vascular stability: A prospective multicenter study. Int J Artif Organs 1987;10(3):157-162.
Lamperi S, Vagge R. Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment. Int J Artif Organs 1979 Sep;2(5):243-247.
Landmann J, Renner N, Gachter A, Thiel G, Harder F. Cyclosporin A and osteonecrosis of the femoral head. J Bone Joint Surg Am 1987 Oct;69(8):1226-1228.
Langman CB, Mazur AT, Baron R, Norman ME. 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity. J Pediatr 1982 May;100(5):815-820.
Lanteri M, Ptasznik R, Constable L, Dawborn JK. Ultrasound changes in the wrist and hand in hemodialysis patients. Clin Nephrol 1997 Dec;48(6):375-380.
Laurent G, Calemard E, Charra B. Dialysis related amyloidosis. Kidney Int Suppl 1988 Mar;24:S32-S34.
Lausten GS, Lemser T, Jensen PK, Egfjord M. Necrosis of the femoral head after kidney transplantation. Clin Transplant 1998 Dec;12(6):572-574.
Lavaud S, Troupance O, Roujoulch H, Fakir M, Melin JP, Chanard J. Carpal tunnel syndrome in hemodialysis patients: effect of dialysis strategy, in Man, Mion, Henderson (eds). Blood Purification in Perspective: New Insights and Future Trends. Cleveland, OH, ISAO Press, 1987, pp 125-8.
Ledermann SE, Johnson A, Dillon MJ, Trompeter RS, Barratt TM. Serum intact parathyroid hormone and ionised calcium concentration in children with renal insufficiency. Pediatr Nephrol 1994 Oct;8(5):561-565.
Lee WT, Padayachi K, Collins JF, Cundy T. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol 1994 Dec;5(6):1344-1348.
Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989 Dec;36(6):1112-1118.
Lerner A, Kramer M, Goldstein S, Caruana R, Epstein S, Raja R. Calcium carbonate. A better phosphate binder than aluminum hydroxide. ASAIO Trans 1986 Jul-Sep;32(1):315-318.
Letteri JM, Ellis KJ, Orofino DP, Ruggieri S, Asad SN, Cohn SH. Altered calcium metabolism in chronic renal failure. Kidney Int 1974 Jul;6(1):45-54.
Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE. Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. Am J Kidney Dis 1996;27(5):652-663.
Levin KE, Gooding GA, Okerlund M, Higgins CB, Norman D, Newton TH, Duh QY, Arnaud CD, Siperstein AE, Zeng QH. Localizing studies in patients with persistent or recurrent hyperparathyroidism. Surgery 1987 Dec;102(6):917-925.
Levitt MD, Vivian AB, Saker BM. Parathyroidectomy in chronic renal failure. Aust N Z J Surg 1986 Mar;56(3):233-239.
Lewis EJ, Tolchin N, Roberts JL. Estimation of the metabolic conversion of acetate to bicarbonate during hemodialysis. Kidney Int Suppl 1980 Sep;Suppl 10:S51-S55.
Lin YF, Shieh SD, Diang LK, Lin SH, Chyr SH, Li BL, Lu KC. Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure. ASAIO J 1994 Jul-Sep;40(3):M440-M444.
Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: A prospective study. South Med J 1993 Dec;86(12):1385-1388.
Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB. Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol 1999 Jul;52(7):631-636.
Lindenau K, Kokot F, Vetter K, Hohmann WD, Werner G, Buder R, Grossmann I, Frohling PT. How to prevent renal osteodystrophy. Contrib Nephrol 1984;37:66-69.
Lindergard B. Changes in bone mineral content evaluated by photon absorptiometry before the start of active uremia treatment. Clin Nephrol 1981 Sep;16(3):126-130.
Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron 1985;39(2):122-129.
Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994;20(3):97-102.
Liou HH, Chiang SS, Tsai SC, Chang CC, Wu SC, Shieh SD, Huang TP. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Chung Hua I Hsueh Tsa Chih (Taipei) 1994 Jun;53(6):319-324.
Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: A new meta-analytic method. Med Decis Making 1993 Oct-Dec;13(4):313-321.
Ljunghall S, Althoff P, Fellstrom B, Marjanovic B, Nisell J, Weiss L, Wide L. Effects on serum parathyroid hormone of intravenous treatment with alfacalcidol in patients on chronic hemodialysis. Nephron 1990;55(4):380-385.
Ljutic D, Cameron JS, Ogg CS, Turner C, Hicks JA, Owen WJ. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure. QJM 1994 Nov;87(11):685-692.
Llach F, Felsenfeld AJ, Coleman MD, Keveney JJ Jr, Pederson JA, Medlock TR. The natural course of dialysis osteomalacia. Kidney Int Suppl 1986 Feb;18:S74-S79.
Llach F, Hervas J, Cerezo S. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 1995 Nov;26(5):845-851.
Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 1998 Oct;32(2 Suppl 2):S48-S54.
Lobo PI, Cortez MS, Stevenson W, Pruett TL. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995 Aug;9(4):277-281.
Locatelli F. Dietary compliance in patients with chronic renal failure: Experience in a northern Italy trial. Contrib Nephrol 1990;81:102-106.
Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991 Jun 1;337(8753):1299-1304.
Locsey L, Gyarmati J. Arthropathy in haemodialysed patients. Acta Med Hung 1986;43(4):413-422.
Loschiavo C, Fabris A, Adami S, et al. Effects of continuous ambulatory peritoneal dialysis (CAPD) on renal osteodystrophy. Perit Dial Int 1985;5(1):53-55.
Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990 May;15(5):458-482.
Lu KC, Shieh SD, Li BL, Chu P, Jan SY, Lin YF. Rapid correction of metabolic acidosis in chronic renal failure: Effect on parathyroid hormone activity. Nephron 1994;67(4):419-424.
Lu YM, Xiao HW, Liang KH. The effects of calcium-regulating-hormone on BMC in patients with CRF. J Tongji Med Univ 1995;15(2):95-97.
Lucas PA, Woodhead JS, Brown RC. Vitamin D3 metabolites in chronic renal failure and after renal transplantation. Nephrol Dial Transplant 1988;3(1):70-76.
Lundgren G, Asaba M, Magnusson G, Pieper R, Alveryd A. The role of parathyroidectomy in the treatment of secondary hyperparathyroidism before and after renal transplantation. Scand J Urol Nephrol Suppl 1977;(42):149-152.
Lyhne N, Bangsgaard Pedersen F. Changes in bone mineral content during long-term CAPD: Indication of a sex-dependent bone mineral loss. Nephrol Dial Transplant 1995;10(3):395-398.
Lysaght MJ, Pollock CA, Moran JE, Ibels LS, Farrell PC. Beta-2 microglobulin removal during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989;9(1):29-35.
Macia M, Coronel F, Navarro JF, Gallego E, Herrero JA, Mendez ML, Chahin J, Garcia J. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD. Clin Nephrol 1997 Sep;48(3):181-184.
Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987 Nov;28(5):222-226.
Madsen S, Olgaard K, Ladefoged J. Bone mineral content in chronic renal failure during long-term treatment with 1alpha-hydroxycholecalciferol. Acta Med Scand 1978;203(5):385-389.
Madsen S, Thaysen JH, Olgaard K, Heerfordt J, Lokkegaard H. Is renal osteodystrophy reversible? Proc Eur Dial Transplant Assoc 1977;14:433-441.
Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987 Oct 17;2(8564):875-877.
Mahmoud MD, Bouche V, Collin P, Girault A. Effects of keto-analogues on phosphocalcic and aminoacid metabolism in dialysed patients: A crossover study. Int J Artif Organs 1989 Nov;12(11):692-696.
Makoff DL, Gordon A, Franklin SS, Gerstein AR, Maxwell MH. Chronic calcium carbonate therapy in uremia. Arch Intern Med 1969 Jan;123(1):15-21.
Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996 Nov;28(5):704-712.
Malberti F, Corradi B, Imbasciati E. Effect of CAPD and hemodialysis on parathyroid function. Adv Perit Dial 1996;12:239-244.
Malberti F, Surian M, Cosci P. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol. Kidney Int Suppl 1993 Jun;41:S125-S130.
Malhotra KK, Gadekar NG, Umashankar P, Bhargava S. Bone disease in chronic renal failure. Indian J Med Res 1968 Nov;56(11):1687-1695.
Mallette LE, Eisenberg KL, Schwaitzberg SD, Suki WN, Noon GP. Total parathyroidectomy and autogenous parathyroid graft placement for treatment of hyperparathyroidism due to chronic renal failure. Am J Surg 1983 Dec;146(6):727-733.
Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984 Dec;26(6):869-874.
Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992 Oct;38:S62-S67.
Malluche HH, Ritz E, Hodgson M, Kutschera J, Krause G, Seiffert U, Gati A, Lange HP. Skeletal lesions and calcium metabolism in early renal failure. Proc Eur Dial Transplant Assoc 1975;11:443-450.
Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int 1976 Apr;9(4):355-362.
Malmaeus J, Akerstrom G, Johansson H, Ljunghall S, Nilsson P, Selking O. Parathyroid surgery in chronic renal insufficiency. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation to the forearm. Acta Chir Scand 1982;148(3):229-238.
Malvy D, Maingourd C, Pengloan J, Bagros P, Nivet H. Effects of severe protein restriction with ketoanalogues in advanced renal failure. J Am Coll Nutr 1999 Oct;18(5):481-486.
Mandolfo S, Malberti F, Farina M, Villa G, Scanziani R, Surian M, Imbasciati E. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure [letter]. Nephrol Dial Transplant 1998 Oct;13(10):2708-2709.
Manji T, Kobayashi K. Effects of 1 alpha-OH-D3 on bone mineral content in the forearm of chronic hemodialyzed patients. Contrib Nephrol 1980;22:39-50.
Manni M, Calabria S, Mantella D, Centorrino M, Dinnella A, Sturniolo A, Coen R, Splendiani G, Coen G. Oral clcitriol: Comparison between the same weekly dose administered as a single vs two divided pulsed doses in secondary hyperparathyroidism of chronic renal failure. Ital J Miner Electrolyte Metab 1997;11(2):61-64.
Mansell MA, Morgan SH, Moore R, Kong CH, Laker MF, Wing AJ. Cardiovascular and acid-base effects of acetate and bicarbonate haemodialysis. Nephrol Dial Transplant 1987;1(4):229-232.
Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999 Sep;14(9):2178-2183.
Marco MP, Martinez I, Amoedo ML, Borras M, Saracho R, Almirall J, Fibla J, Fernandez E. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney Int 1999 Oct;56(4):1349-1353.
Marsden SN, Parkinson IS, Ward MK, Ellis HA, Kerr DN. Evidence for aluminium accumulation in renal failure. Proc Eur Dial Transplant Assoc 1979;16:588-596.
Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998 Aug;9(8):1427-1432.
Martin RC 2nd, Greenwell D, Flynn MB. Initial neck exploration for untreated hyperparathyroidism. Am Surg 2000 Mar;66(3):269-272.
Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11 Suppl 3:22-28.
Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997 Apr;29(4):496-502.
Martinez ME, Selgas R, Miguel JL, Balaguer G, Sanchez-Cabezudo MJ, Llach F. Osteocalcin levels in uremic patients: Influence of calcitriol treatment through two different routes and type of dialysis. Nephron 1991;59(3):429-433.
Marumo F, Sakurai K, Sato N, Shimada H, Iwanami S. Deranged mineral content in the bone of patients with chronic renal failure, estimated by computed tomography. Int J Artif Organs 1985 Mar;8(2):95-100.
Marumo F, Umetani N, Sato N, Takahashi Y. Deferoxamine (DFO): The effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease. Sangyo Ika Daigaku Zasshi 1987 Mar 20;9 Suppl:140-152.
Mason RS, Moddel D, McElduff A, Stewart JH, Mahony JF, Posen S. The relevance of 25-hydroxycalciferol measurements in sera of patients with renal failure. Aust N Z J Med 1979 Jun;9(3):257-260.
Massry SG, Coburn JW, Popovtzer MM, Shinaberger JH, Maxwell MH, Kleeman CR. Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation. Arch Intern Med 1969 Oct;124(4):431-441.
Massry SG, Gruber H, Arif SR, Sherman D, Goldstein DA, Letteri JM. Use of 1.25(OH)2D3 in the treatment of renal osteodystrophy in patients with moderate renal failure, in Frame R, Potts J (eds): Clinical Disorders of Bone and Mineral Metabolism. New York, NY, Excerpta Medica, 1983, pp 260-262.
Massry SG, Llach F, Singer FR, Kurokawa K, Coburn JW. Homeostasis and action of parathyroid hormone in normal man and patients with mild renal failure. Proc Eur Dial Transplant Assoc 1975;11:451-456.
Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994 Mar;40(3):358-363.
Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W. Renal bone disease in pediatric and young adult patients on hemodialysis in a children’s hospital. J Am Soc Nephrol 1993 Jun;3(12):1938-1946.
Matsuura P, Waters RL, Adkins RH, Rothman S, Gurbani N, Sie I. Comparison of computerized tomography parameters of the cervical spine in normal control subjects and spinal cord-injured patients. J Bone Joint Surg Am 1989 Feb;71(2):183-188.
Max MH, Flint LM, Richardson JD, Ferris FZ, Nagar D. Total parathyroidectomy and parathyroid autotransplantation in patients with chronic renal failure. Surg Gynecol Obstet 1981 Aug;153(2):177-180.
Mayer G, Thum J, Woloszczuk W, Graf H. Beta-2-microglobulin in hemodialysis patients. Effects of different dialyzers and different dialysis procedures. Am J Nephrol 1988;8(4):280-284.
Mayer M. Qigong and hypertension: A critique of research. J Altern Complement Med 1999;5(4):371-382.
Maynard JC, Cruz C, Kleerekoper M, Levin NW. Blood pressure response to changes in serum ionized calcium during hemodialysis [published erratum appears in Ann Intern Med 1986 Oct;105(4):635]. Ann Intern Med 1986 Mar;104(3):358-361.
Mazzaferro S, Coen G, Ballanti P, Bondatti F, Bonucci E, Pasquali M, Sardella D, Tomei E, Taggi F. Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. Nephron 1990;56(3):261-266.
Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Costantini S, Chicca S, De Meo S, Perruzza I, Sardella D, Taggi F, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995;10(1):52-58.
McCarey D, Spooner R, Jagger C, McLellan AR, Jardine AG. The BSM-1 vitamin D receptor polymorphism and secondary hyperparathyroidism [letter; comment]. Nephrol Dial Transplant 1998 Mar;13(3):811-812.
McCarron DA, Lenfesty B, Thier A, Vetto M, Barry J, Krutzik S, Bennett WM. Total parathyroidectomy for post-transplantation hyperparathyroidism. Proc Clin Dial Transplant Forum 1980;10:51-55.
McCarron DA, Lenfesty B, Vetto M, Barry J, Bennett WM. Total parathyroidectomy for posttransplantation hyperparathyroidism. Transplantation 1985 Sep;40(3):266-269.
McCarthy JT, Klee GG, Kao PC, Hodgson SF. Serum bioactive parathyroid hormone in hemodialysis patients. J Clin Endocrinol Metab 1989 Feb;68(2):340-345.
McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J M 1990 MAR;74(275):257-276.
McCarthy JT, Williams AW, Johnson WJ. Serum beta 2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J Lab Clin Med 1994 Apr;123(4):495-505.
McCrory WW, Gertner JM, Burke FM, Pimental CT, Nemery RL. Effects of dietary phosphate restriction in children with chronic renal failure. J Pediatr 1987 Sep;111(3):410-412.
McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: Comparison of immunosuppressive regimens. Clin Transplant 1995 Feb;9(1):20-24.
McMahon LP, Radford J, Dawborn JK. Shoulder ultrasound in dialysis related amyloidosis. Clin Nephrol 1991 May;35(5):227-232.
McSherry E, Morris RC Jr. Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 1978 Feb;61(2):509-527.
Meakins JL, Milne CA, Hollomby DJ, Goltzman D. Total parathyroidectomy: parathyroid hormone levels and supernumerary glands in hemodialysis patients. Clin Invest Med 1984;7(1):21-25.
Meeks AC, Sims DG. Treatment of renal failure in neonates . Arch Dis Child 1988 Nov;63(11):1372-1376.
Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987 Sep;32(3):388-394.
Meema HE, Oreopoulos DG, Uldall PR. The influence of age and sex on bone resorption of secondary hyperparathyroidism in renal osteodystrophy. Calcif Tissue Int 1984 Jan;36(1):25-30.
Mehta BR, Fischer D, Ahmad M, Dubose TD Jr. Effects of acetate and bicarbonate hemodialysis on cardiac function in chronic dialysis patients. Kidney Int 1983 Dec;24(6):782-787.
Meisinger E, Strauch M. Controlled trial of two keto acid supplements on renal function, nutritional status, and bone metabolism in uremic patients. Kidney Int 1987 Oct;32(Suppl 22):S170-S173.
Meisinger E, Strauch M. The influence of two different essential amino acid/keto analogue preparations on the clinical status of patients with chronic renal failure. Z Ernahrungswiss 1985 Jun;24(2):96-104.
Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, de Wardener HE. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1919-1924.
Mengozzi G, Baldi C, Aimo G, Mullineris B, Salvo R, Biasiol S, Pagni R, Gasparri G. Optimizing efficacy of quick parathyroid hormone determination in the operating theater. Int J Biol Markers 2000 Apr-Jun;15(2):153-160.
Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, Di Loreto PL, Bresadola F, Mioni G. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998 Nov;54(5):1704-1713.
Messa P, Vallone C, Mioni G, Geatti O, Turrin D, Passoni N, Cruciatti A. Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 1994 Dec;46(6):1713-1720.
Milas NC, Nowalk MP, Akpele L, Castaldo L, Coyne T, Doroshenko L, Kigawa L, Korzec-Ramirez D, Scherch LK, Snetselaar L. Factors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 1995 Nov;95(11):1295-1300.
Miller D, Taber TE, Hegeman TF. Calcium carbonate powder as a phosphate binder. ASAIO Trans 1989 Jul-Sep;35(3):322-324.
Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW. Clearance of aluminum by hemodialysis: Effect of desferrioxamine. Kidney Int Suppl 1986 Feb;29(Suppl 18):S100-S103.
Milliner DS, Nebeker HG, Ott SM, Andress DL, Sherrard DJ, Alfrey AC, Slatopolsky EA, Coburn JW. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984 Dec;101(6):775-779.
Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990 Nov;38(5):931-936.
Mioli VA, Balestra E, Bibiano L, Dellabella S, Fanciulli E, Gaffi G, Perilli A, Petroselli F, Ricciatti AM, Carletti P. Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients. Int J Artif Organs 1994 Nov;17(11):576-580.
Mirahmadi KS, Duffy BS, Shinaberger JH, Jowsey J, Massry SG, Coburn JW. A controlled evaluation of clinical and metabolic effects of dialysate calcium levels during regular hemodialysis. Trans Am Soc Artif Intern Organs 1971;17:118-123.
Miura Y, Ishiyama T, Inomata A, Takeda T, Senma S, Okuyama K, Suzuki Y. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis. Nephron 1992;60(3):268-273.
The Modification of Diet in Renal Disease Study: Design, methods, and results from the feasibility study. Am J Kidney Dis 1992 Jul;20(1):18-33.
Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: A randomized trial. Nephrol Dial Transplant 1998 May;13(5):1234-1241.
Moe SM, Yu BOH, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993;22(2):300-307.
Mojiminiyi S, Shepstone BJ. Bone marrow immunoscintigraphy [letter]. Lancet 1989 Apr 1;1(8640):725-726. [letter]
Molitoris BA, Alfrey PS, Miller NL, Hasbargen JA, Kaehney WD, Alfrey AC, Smith BJ. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation. Kidney Int 1987 Apr;31(4):986-991.
Monchik JM, Bendinelli C, Passero MA Jr, Roggin KK. Subcutaneous forearm transplantation of autologous parathyroid tissue in patients with renal hyperparathyroidism. Surgery 1999 Dec;126(6):1152-1158; discussion 1158-1159.
Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996;11 Suppl 3:111-120.
Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000;11(6):1093-1099.
Monzani G, Bergesio F, Ciuti R, Ciciani AM, Martinelli F, Rosati A, Salvadori M. Lp(a) levels: Effects of progressive chronic renal failure and dietary manipulation. J Nephrol 1997 Jan-Feb;10(1):41-45.
Moolenaar W, Heslinga JM, Arndt JW, v.d. Velde CJ, Pauwels EK, Valentijn RM. 201Tl-99mTc subtraction scintigraphy in secondary hyperparathyroidism of chronic renal failure. Nephrol Dial Transplant 1988;3(2):166-168.
Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, Kerr DN. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J M 1983 Summer;52(207):332-348.
Mora Palma FJ, Lorenzo Sellares V, Ellis HA, Ward MK, Kerr DN. Osteomalacia in chronic renal failure before dialysis. Proc Eur Dial Transplant Assoc 1983;19:188-194.
Morduchowicz G, Sulkes J, Aizic S, Gabbay U, Winkler J, Boner G. Compliance in hemodialysis patients: A multivariate regression analysis. Nephron 1993;64(3):365-368.
Moreno A, Torregrosa JV, Pons F, Campistol JM, Martinez De Osaba MJ, Oppenheimer F. Bone mineral density after renal transplantation: Long-term follow-up. Transplant Proc 1999;31(6):2322-2323.
Moriniere P, Boudailliez B, Hocine C, Belbrik S, Renaud H, Westeel PF, Solal MC, Fournier A. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: A long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3. Nephrol Dial Transplant 1989;4(12):1045-1053.
Moriniere P, Cohen-Solal M, Belbrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL, et al. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989;53(2):93-101.
Moriniere P, Esper NE, Viron B, Judieth D, Bourgeon B, Farquet C, Gheerbrant J, Chapuy MC, Orshoven AV, Pamphile R, Fournier A. Improvement of severe secondary hyperparathyroidism in dialysis paitients by intravenous (OH) vitamin D3, oral CaCO3 and low dialysate calcium. Kidney Int 1993;43(Suppl 41):S121-S124.
Moriniere P, Fournier A, Leflon A, Herve M, Sebert JL, Gregoire I, Bataille P, Gueris J. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 1985;39(4):309-315.
Moriniere P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine C, Marie A, Leflon P, Roche D, et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988;3(5):651-656.
Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant 2000 May;15(5):659-667.
Morita A, Tabata T, Inoue T, Nishizawa Y, Morii H. The effect of oral 1 alpha-hydroxycalciferol treatment on bone mineral density in hemodialysis patients. Clin Nephrol 1996 Dec;46(6):389-393.
Morita A, Tabata T, Koyama H, Emoto M, Inoue T, Miki T, Nishizawa Y, Morii H. A two-site immunochemiluminometric assay for intact parathyroid hormone and its clinical utility in hemodialysis patients. Clin Nephrol 1992 Sep;38(3):154-157.
Morniere P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R, et al. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2. Nephron 1992;60(2):154-163.
Morris PJ, Chan L, French ME, Ting A. Low dose oral prednisolone in renal transplantation. Lancet 1982 Mar 6;1(8271):525-527.
Morton AR, Hercz G. Hypercalcemia in dialysis patients: Comparison of diagnostic methods. Dial Transplant 1991;20:661-667.
Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: Data-analytic approaches and some additional considerations. Stat Med 1993 Jul 30;12(14):1293-1316.
Mountokalakis T, Symvoulidis A, Ntalles K, Ikkos D. Bone loss in chronic renal failure [letter]. Lancet 1977 Feb 12;1(8007):363.
Mourad G, Argiles A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996 May;7(5):798-804.
Mozes MF, Soper WD, Jonasson O, Lang GR. Total parathyroidectomy and autotransplantation in secondary hyperparathyroidism. Arch Surg 1980 Apr;115(4):378-385.
Mrowka C, Schiffl H. Comparative evaluation of beta 2-microglobulin removal by different hemodialysis membranes: A six-year follow-up [letter]. Nephron 1993;63(3):368-369.
Muirhead N, Adami S, Fraser RA, Catto GR, Edward N, O’Riordan JL. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues. Proc Eur Dial Transplant Assoc 1981;18:567-572.
Muirhead N, Adami S, Sandler LM, Fraser RA, Catto GR, Edward N, O’Riordan JL. Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy. Q J M 1982;51(204):427-444.
Munoz-Gomez J, Gomez-Perez R, Llopart-Buisan E, Sole-Arques M. Clinical picture of the amyloid arthropathy in patients with chronic renal failure maintained on haemodialysis using cellulose membranes. Ann Rheum Dis 1987 Aug;46(8):573-579.
Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y. Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3. Nephron 1991;58(3):288-294.
Myrick SR, Radomski JS, Michael HJ, Cohn HE. Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure by sub-total parathyroidectomy. Am Surg 1994 Aug;60(8):638-640.
Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis 1998 Sep;32(3):464-469.
Naik RB, Gosling P, Price CP. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J 1977 May 21;1(6072):1307-1310.
Naiker IP, Govender S, Naicker S, Dawood S, Haffejee AA, Seedat YK. Avascular necrosis of bone following renal transplantation. S Afr Med J 1993;83(9):646-649.
Nakagawa M, Emoto A, Nasu N, Hirata Y, Sato F, Li W, Imagawa M, Nomura Y. Calcium supplement necessary to correct hypocalcemia after total parathyroidectomy for renal osteodystrophy. Int J Urol 2000 Feb;7(2):35-40.
Nakazawa R, Azuma N, Suzuki M, Nakatani M, Nankou T, Furuyoshi S, Yasuda A, Takata S, Tani N, Kobayashi F. A new treatment for dialysis-related amyloidosis with ß 2-microglobulin absorbent column. Int J Artif Organs 1993;16(12):823-829.
Neale TJ, Watson EC. Parathyroid surgery in chronic renal failure. N Z Med J 1985 Nov 13;98(790):939-944.
Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW. Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int Suppl 1986 Feb;18:S96-S99.
Nehme D, Rondeau E, Paillard F, Moreau JF, Nussaume O, Kanfer A, Sraer JD. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant 1989;4(2):123-128.
Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO, Pepys MB. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 1991 Aug 10;338(8763):335-339.
Neonakis E, Wheeler MH, Krishnan H. Renal hyperparathyroidism—A retrospective study. Acta Chir Austriaca 1996;28(Suppl 124):34-38.
Neonakis E, Wheeler MH, Krishnan H, Coles GA, Davies F, Woodhead JS. Results of surgical treatment of renal hyperparathyroidism. Arch Surg 1995 Jun;130(6):643-648.
Neubauer E, Neubauer N, Ritz E, Dreikorn K, Krause KH. Bone mineral content after renal transplantation. Placebo-controlled prospective study with 1,25-dihydroxy vitamin D3. Klin Wochenschr 1984 Jan 16;62(2):93-96.
Neumann DR, Esselstyn CB Jr, Madera A, Wong CO, Lieber M. Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography. J Clin Endocrinol Metab 1998 Nov;83(11):3867-3871.
Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 1998 Apr 30;17(8):857-872.
Nichols P, Owen JP, Ellis HA, Farndon JR, Kelly PJ, Ward MK. Parathyroidectomy in chronic renal failure: A nine-year follow-up study. Q J M 1990 Nov;77(283):1175-1193.
Nielsen HE. Bone mineral content in renal transplant patients. Clin Nephrol 1978 Nov;10(5):196-200.
Nielsen HE, Melsen F, Lund B, Sorensen OH, Christensen MS. Serum-25-hydroxycholecalciferol and renal osteodystrophy [letter]. Lancet 1977 Apr 2;1(8014):754-755.
Nilsson P, Danielson BG, Grefberg N, Wide L. Secondary hyperparathyroidism in diabetic and nondiabetic patients on long-term continuous ambulatory peritoneal dialysis (CAPD). Scand J Urol Nephrol 1985;19(1):59-65.
Nilsson P, Melsen F, Malmaeus J, Danielson BG, Mosekilde L. Relationships between calcium and phosphorus homeostasis, parathyroid hormone levels, bone aluminum, and bone histomorphometry in patients on maintenance hemodialysis. Bone 1985;6(1):21-27.
Nisbet AP, Shaw P, Taube D, Edwards S, Maisey MN, Mashiter G. 51Cr-EDTA/99Tcm-MDP ratio: A simple non-invasive method for assessing renal osteodystrophy. Br J Radiol 1989 May;62(737):438-442.
Nishitani H, Yamakawa M, Nishizawa Y, Morii H. Bone mineral loss in patients on maintenance hemodialysis with hyperphosphatemia treated with 1 alpha-hydroxycholecalciferol and calcium carbonate. J Nutr Sci Vitaminol (Tokyo) 1991 Dec;37 Suppl:S113-S118.
Nishiyama K, Okinaga A. Osteonecrosis after renal transplantation in children. Clin Orthop 1993;(295):168-171.
Nomoto Y, Kawaguchi Y, Ohira S, Yuri T, Kubo H, Kubota M, Nihei H, Nakao T, Hara S, Nakamoto M, et al. Carpal tunnel syndrome in patients undergoing CAPD: A collaborative study in 143 centers. Am J Nephrol 1995;15(4):295-299.
Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988 Nov;67(5):929-936.
Noree LO, Bergstrom J. Treatment of chronic uremic patients with protein-poor diet and oral supply of essential amino acids. II. Clinical results of long-term treatment. Clin Nephrol 1975;3(5):195-203.
Norman ME, Mazur AT, Borden S 4th, Gruskin A, Anast C, Baron R, Rasmussen H. Early diagnosis of juvenile renal osteodystrophy. J Pediatr 1980 Aug 1;97(2):226-232.
O’Leary DP, White HJ. Parathyroidectomy for hyperparathyroidism associated with renal disease. Ann R Coll Surg Engl 1995 Mar;77(2):97-101.
O’Riordan JL, Page J, Kerr DN, Walls J, Moorhead J, Crockett RE, Franz H, Ritz E. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy. Q J M 1970 Jul;39(155):359-376.
Oda H, Yorioka N, Takemasa A, Shigemoto K, Harada S, Ito T, Masaki T, Yamakido M. Renal osteodystrophy in hemodialysis patients. Hiroshima J Med Sci 1995 Sep;44(3):83-88.
Offermann G, von Herrath D, Schaefer K. Serum 25-hydroxycholecalciferol in uremia. Nephron 1974;13(4):269-277.
Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. Kidney Int 1992 Jun;41(6):1646-1652.
Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Leger A, Lopez J, Acuna G, Petraglia A, Alvarez A, Caorsi H, Drueke T, Ambrosoni P. [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations. Nephrol Dial Transplant 2000 Aug;15(8):1201-1206. [(99m)Tc]
Onishi S, Andress DL, Maloney NA, Coburn JW, Sherrard DJ. Beta 2-microglobulin deposition in bone in chronic renal failure. Kidney Int 1991 May;39(5):990-995.
Ott SM, Andress DL, Nebeker HG, et al. Changes in bone histology after treatment with desferrioxamine. Kidney Int 1986;28(Suppl 18):S108-S113.
Otte KE, Lillevang ST, Rasmussen AG, Christensen HK, Pedersen FB. Acetate or bicarbonate for haemodialysis: A randomised, double-blind controlled trial. Nephrol Dial Transplant 1990;5(11):931-936.
Ouseph R, Leiser JD, Moe SM. Calcitriol and the parathyroid hormone-ionized calcium curve: A comparison of methodologic approaches. J Am Soc Nephrol 1996 Mar;7(3):497-505.
Owen JP, Parnell AP, Keir MJ, Ellis HA, Wilkinson R, Ward MK, Elliott RW. Critical analysis of the use of skeletal surveys in patients with chronic renal failure. Clin Radiol 1988 Nov;39(6):578-582.
Pagel MD, Ahmad S, Vizzo JE, Scribner BH. Acetate and bicarbonate fluctuations and acetate intolerance during dialysis. Kidney Int 1982 Mar;21(3):513-518.
Panczyk-Tomaszewska M, Ziolkowska H, Debinski A, Sieniawska M. Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 2000 Mar;15(3):375-378.
Panichi V, Andreini B, Bianchi Am, Parrini M, Ferdeghini M, Finato V, Giovannini L, Migliori M, De Pietro S, Palla R. Calcitriol therapy in predialytic secondary hyperparathyroidism: Effects of oral pulses versus a daily oral regimen. J Nephrol 1995;8(4):206-209.
Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, Ferdeghini M, Palla R. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol 1998 Apr;49(4):245-250.
Papadakis J, Brown CB, Cameron JS, Adu D, Bewick M, Donaghey R, Ogg CS, Rudge C, Williams DG, Taube D. High versus ‘low’ dose corticosteroids in recipients of cadaveric kidneys: prospective controlled trial. Br Med J (Clin Res Ed) 1983 Apr 2;286(6371):1097-1100.
Parker CR, Freemont AJ, Blackwell PJ, Grainge MJ, Hosking DJ. Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 1999;14(11):1943-1951.
Pascual N, Andrea C, Zaleski M, Hernandez J, Goicoechea M. Incidence of hypercalcaemia in haemodialysis patients. EDTNA ERCA J 1997 Jul-Sep;23(3):48-50.
Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD. Clin Nephrol 1989 Aug;32(2):96-100.
Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. Surgery 1988 Jan;103(1):63-68.
Paunier L, Salusky IB, Slatopolsky E, Kangarloo H, Kopple JD, Horst RL, Coburn JW, Fine RN. Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis. Pediatr Res 1984 Aug;18(8):742-747.
Pazianas M, Ciacci C, Eastwood JB, Macrae KD, Phillips ME. Long term oral calcitriol in patients on chronic hemodialysis. J Nephrol 1995;8(1):45-52.
Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D. Renal osteodystrophy in diabetic patients. Kidney Int 1993;44(1):159-164.
Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D. Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res 1995 Jan;10(1):149-156.
Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 1992;41(5):1374-1382.
Peng SJ, Yang CS, Ferng SH, Chen LY. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab 1997;23(1):13-18.
Petersen J, Moore RM Jr, Kaczmarek RG, Singh B, Yeh I, Hamburger S, Kankam M. The effects of reprocessing cuprophane and polysulfone dialyzers on beta 2-microglobulin removal from hemodialysis patients [published erratum appears in Am J Kidney Dis 1991 Jul;18(1):144]. Am J Kidney Dis 1991 Feb;17(2):174-178.
Petersen LJ, Rudnicki M, Hojsted J. Long-term oral calcium supplementation reduces diastolic blood pressure in end stage renal disease. A randomized, double-blind, placebo controlled study. Int J Artif Organs 1994 Jan;17(1):37-40.
Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 1994;9(8):1121-1124.
Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: A cross-sectional and longitudinal study. Am J Kidney Dis 1996 Jul;28(1):105-114.
Pierides AM, Simpson W, Stainsby D, Alvarez-ude F, Uldall PR. Avascular necrosis of bone following renal transplantation. Q J M 1975 Jul;44(175):459-480.
Pietila K, Mustonen J, Morsky P, Seppala E, Pasternack A, Koivula T. Effect of one haemodialysis treatment on the plasma concentrations of intact parathyroid hormone and ionised calcium: Usefulness of end-dialysis values in evaluating the suppressibility of hyperparathyroidism. Nephrol Dial Transplant 1989;4(2):115-118.
Piraino B, Bernardini J, Holley J, Johnston JR, Perlmutter JA, Martis L. Calcium mass transfer in peritoneal dialysis patients using 2.5 mEq/l calcium dialysate. Clin Nephrol 1992 Jan;37(1):48-51.
Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988 Aug;30(2):57-62.
Piraino B, Chen T, Puschett JB. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients. Am J Nephrol 1989;9(3):190-197.
Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988 Nov;67(5):876-881.
Pizzarelli F, Fabrizi F, Postorino M, Curatola G, Zoccali C, Maggiore Q. Parathyroidectomy and blood pressure in hemodialysis patients. Nephron 1993;63(4):384-389.
Plante GE. Urinary phosphate excretion determines the progression of renal disease. Kidney Int Suppl 1989 Nov;27:S128-S132.
Pons F, Torregrosa JV, Vidal-Sicart S, Sabater L, Fuster D, Fernandez-Cruz L, Herranz R. Preoperative parathyroid gland localization with technetium-99m sestamibi in secondary hyperparathyroidism. Eur J Nucl Med 1997 Dec;24(12):1494-1498.
Ponticelli C, Civati G, Tarantino A, Quarto di Palo F, Corbetta G, Minetti L, Vegeto A, Belli L. Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. J Am Soc Nephrol 1996 May;7(5):792-797.
Popovtzer MM, Levi J, Bar-Khayim Y, Shasha SM, Boner G, Bernheim J, Chaimovitz C, Rubinger D, Gafter U, Gazit D, Edelstein S, Slatopolsky E. Assessment of combined 24,25(OH)D and 1a(OH)D therapy for bone disease in dialysis patients. Bone 1992;13(5):369-377.
Popovtzer MM, Massry SG, Makoff DL, Maxwell MH, Kleeman CR. Renal handling of phosphate in patients with chronic renal failure. The role of variations in serum phosphorus and parathyroid activity. Isr J Med Sci 1969 Sep-Oct;5(5):1018-1023.
Popovtzer MM, Michael UF, Johnson-Dial KS, Ronstadt C, Nelson D, Ogden DA. Dietary calcium deprivation and secondary hyperparathyroidism in patients treated with chronic dialysis. Miner Electrolyte Metab 1986;12(5-6):298-302.
Potter DE, Genant HK, Salvatierra O. Avascular necrosis of bone after renal transplantation. Am J Dis Child 1978 Nov;132(11):1125-1129.
Prince RL, Hutchison BG, Kent JC, Kent GN, Retallack RW. Calcitriol deficiency with retained synthetic reserve in chronic renal failure. Kidney Int 1988 Mar;33(3):722-728.
Przedlacki J, Manelius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 1995;69(4):433-437.
Punch JD, Merion RM, Thompson NW. Hyperparathyroidism associated with end stage renal disease and transplantation. Acta Chir Austriaca 1996;28(Suppl 124):39-41.
Punch JD, Thompson NW, Merion RM, Van Heerden JA, Schulak JA, Berne TV. Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients: A 25-year single-center experience. Arch Surg 1995;130(5):538-543.
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995 Oct;26(4):622-631.
Quarello F, Bonello F, Boero R, Maffei S, Beltrame G, Belardi P, Scalzo B, Guarena C, Piccoli G, Piccoli G. CAPD in a large population: A 7-year experience. Adv Perit Dial 1989;5:56-62.
Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992 Jul;75(1):145-150.
Radke HM, Sherrard DJ, Baylink DJ. Near-total parathyroidectomy in chronic dialysis patients. Am Surg 1976 Jul;42(7):463-466.
Rault R. Optimal dialysate bicarbonate during hemodialysis. ASAIO Trans 1991 Jul-Sep;37(3):M372-M373.
Recker R, Schoenfeld P, Letteri J, Slatopolsky E, Goldsmith R, Brickman A. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 1978 May 15;138 Spec No:857-863.
Recker RR, Saville PD. Calcium absorption in renal failure: Its relationship to blood urea nitrogen, dietary calcium intake, time on dialysis, and other variables. J Lab Clin Med 1971 Sep;78(3):380-388.
Reduction of dietary protein and phosphorus in the Modification of Diet in Renal Disease Feasibility Study. The MDRD Study Group. J Am Diet Assoc 1994 Sep;94(9):986-990; quiz 991-992.
Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6(3):162-169.
Renaud H, Atik A, Herve M, Moriniere P, Hocine C, Belbrik S, Fournier A. Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: Lack of influence of calcium carbonate. Nephron 1988;48(1):28-32.
Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998 Aug;13(8):2037-2040.
Rickers H, Christiansen C, Christensen P, Christensen M, Rodbro P. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron 1985;39(3):267-271.
Rickers H, Christiansen C, Christensen P, et al. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron 1985;39(3):267-271.
Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study. Nephrol Dial Transplant 1993;8(4):341-346.
Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 1998;8(1):47-52.
Risler T, Braun N, Hanel KD, Kuhlmann U, Skroch D, Muller GA. Do different dialysis-membranes affect Beta 2-microglobulin kinetics during chronic hemodialysis. Int J Artif Organs 1994;17(11):581-584.
Ritz E, Kuster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995 Dec;10(12):2228-2234.
Ritz E, Mehls O, Bommer J, Schmidt-Gayk H, Fiegel P, Reitinger H. Vascular calcifications under maintenance hemodialysis. Klin Wochenschr 1977 Apr 15;55(8):375-378.
Ritz E, Prager P, Krempien B, Bommer J, Malluche HH, Schmidt-Gayk H. Skeletal X-ray findings and bone histology in patients on hemodialysis. Kidney Int 1978 Apr;13(4):316-323.
Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999 Sep;56(3):1084-1093.
Rizzelli S, Alfonso L, Corliano C, Patruno P, Sozzo E, Mastrangelo F. Biofiltration with bicarbonate as dialysate buffer. Int J Artif Organs 1986 Dec;9 Suppl 3:55-56.
Rodriquez JM, Tezelman S, Siperstein AE, Duh QY, Higgins C, Morita E, Dowd CF, Clark OH. Localization procedures in patients with persistent or recurrent hyperparathyroidism. Arch Surg 1994 Aug;129(8):870-875.
Romanini D, Gazo A, Bellazzi R, de Vincenzi A, Nai M, Santagostino M. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD. Adv Perit Dial 1994;10:267-269.
Rosman JB, Donker AJ, Meijer S, Sluiter WJ, Piers-Becht TP, van der Hem GK. Two years’ experience with protein restriction in chronic renal failure. Contrib Nephrol 1986;53:109-120.
Rosman JB, Langer K, Brandl M, Piers-Becht TP, van der Hem GK, ter Wee PM, Donker AJ. Protein-restricted diets in chronic renal failure: A four year follow-up shows limited indications. Kidney Int Suppl 1989 Nov;27:S96-S102.
Rostaing L, Moreau-Gaudry X, Baron E, Cisterne JM, Monrozies-Bernadet P, Durand D. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997 Apr;47(4):248-255.
Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988 Nov;85(5):651-657.
Rothmund M, Wagner PK. Total parathyroidectomy and autotransplantation of parathyroid tissue for renal hyperparathyroidism. A one- to six-year follow-up. Ann Surg 1983 Jan;197(1):7-16.
Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: A randomized trial. World J Surg 1991 Nov-Dec;15(6):745-750.
Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 1989 Mar;13(3):194-199.
Rubin LA, Fam AG, Rubenstein J, Campbell J, Saiphoo C. Erosive azotemic osteoarthropathy. Arthritis Rheum 1984 Oct;27(10):1086-1094.
Ruderman RJ, Poehling GG, Gray R, Nardone M, Goodman W, Seigler HF. Orthopedic complications of renal transplantation in children. Transplant Proc 1979 Mar;11(1):104-106.
Rudnicki M, Hojsted J, Petersen LJ, Sorensen HA, Hyldstrup L, Transbol I. Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: A randomized double-blind placebo-controlled study. Nephron 1993;65(3):369-374.
Rudnicki M, Hyldstrup L, Petersen LJ, Hojsted J, Transbol I. Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: A randomized double-blind placebo-controlled study. Miner Electrolyte Metab 1994;20(3):130-134.
Rudnicki M, McNair P, Transbol I, Nielsen B. Lack of relationship between parathyroid hormone and 1,25-dihydroxyvitamin D in chronic renal failure. Nephron 1991;58(2):144-149.
Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour JP. Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 1994 Jan;45(1):245-252.
Rushe H, Ugee HM. Assessing adherence to dietary recommendations for hemodialysis patients: The Renal Adherence Attitudes Questionnaire (RAAQ) and the Renal Adherence Behaviour Questionnaire (RABQ). J Psychosom Res 1998 Aug;45(2):149-157.
Rutter M. Behavioral studies: Questions and findings on the concept of a distinctive syndrome, in Rutter M (ed): Developmental Neuropsychology. New York, NY, Guilford Press, 1983, pp 259-279.
Saha H, Pietila K, Mustonen J, Pasternack A, Morsky P, Seppala E, Reinikainen P. Acute effects of calcium carbonate and citrate on secondary hyperparathyroidism in chronic renal failure. Am J Nephrol 1991;11(6):465-469.
Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988 May;33(5):975-982.
Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986 May;108(5 Pt 1):767-770.
Salusky IB, Goodman WG, Kuizon BD. Consequences of intermittent calcitriol therapy in pediatric patients with secondary hyperparathyroidism. Perit Dial Int 1999;19 Suppl 2:S441-S444.
Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 1998 Sep;54(3):907-914.
Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994 Jan;45(1):253-258.
Sanchez C, Bajo A, Selgas R, Mate A, Millan I, Martinez E, Lopez-Barea F. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000 Nov;36(5):953-961.
Sanders C, Frank MS, Rostand SG, Rutsky EA, Barnes GT, Fraser RG. Metastatic calcification of the heart and lungs in end-stage renal disease: Detection and quantification by dual-energy digital chest radiography. AJR Am J Roentgenol 1987 Nov;149(5):881-887.
Santiago-Delpin E. Outcome of young and elderly diabetic patients on ambulatory peritoneal dialysis: The experience of a community hospital in Puerto Rico [editorial; comment]. P R Health Sci J 1996 Jun;15(2):83-84.
Santoro A, Ferrari G, Bolzani R, Spongano M, Zucchelli P. Regulation of base balance in bicarbonate hemofiltration. Int J Artif Organs 1994 Jan;17(1):27-36.
Sarkozi L, Szabo A. Effect of hemodialysis on the distribution of phosphates in blood. Clin Physiol Biochem 1989;7(3-4):184-188.
Scalamogna A, Imbasciati E, De Vecchi A, Castelnovo C, Pagliari B, De Cristofaro V, Ponticelli C. Beta-2 microglobulin in patients on peritoneal dialysis and hemodialysis. Perit Dial Int 1989;9(1):37-40.
Schaadt O, Tougaard L. The degree of bone mineralization in chronic renal failure estimated from phosphorus/hydroxyproline ratio in bone biopsies. Acta Med Scand 1975 Jul-Aug;198(1-2):91-93.
Schaeffer J, Ehlerding G, Floge J, Koch KM, Shaldon S. Beta 2-microglobulin amyloidosis: Why and how to look for it. Clin Nephrol 1995 Nov;44 Suppl 1:S3-S9.
Schaffer J, Burchert W, Floege J, Gielow P, Kionka C, Linke RP, Weiss EH, Shaldon S, Koch KM. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of abeta2m amyloid in dialysis patients. Kidney Int 2000 Aug;58(2):873-880.
Scheumann GF, Finkemeyr SH, Nonnast-Daniel B, Dralle H, Pichlmayr R. Surgical approach to parathyroid hyperplasia in secondary HPT—The Hannover experience. Acta Chir Austriaca 1996;28(Suppl 124):42-43.
Scheumann GF, Holch M, Nerlich ML, Brandis A, Ostertag H, Tscherne H. Pathological fractures and lytic bone lesion of the femoral neck associated with beta 2-microglobulin amyloid deposition in long-term dialysis patients. Arch Orthop Trauma Surg 1991;110(2):93-97.
Schiffl H, D’Agostini B, Held E. Removal of beta 2-microglobulin by hemodialysis and hemofiltration: A four year follow up. Biomater Artif Cells Immobilization Biotechnol 1992;20(5):1223-1232.
Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant 2000 Jun;15(6):840-845.
Schmicker R, Froehling PT, Goetz KH, Kaschube I, Rakette I, Vetter K. Influence of low protein diet supplemented with amino acids and keto acids on the progression of chronic renal failure. Contrib Nephrol 1986;53:121-127.
Schmicker R, Vetter K, Lindenau K, Frohling PT, Kokot F. Conservative long-term treatment of chronic renal failure with keto acid and amino acid supplementation. Infusionsther Klin Ernahr 1987;14(Suppl 5):34-38.
Schmid T, Muller P, Spelsberg F. Parathyroidectomy after renal transplantation: A retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997 Nov;12(11):2393-2396.
Schmidt-Gayk H, Stengel R, Haueisen H, Hufner M, Ritz E, Jakobs KH. Hyperparathyoidism: Influence of glomerular filtration rate on urinary excretion of cyclic AMP. Klin Wochenschr 1977 Mar 15;55(6):275-281.
Schmidt S, Chudek J, Karkoszka H, Heemann U, Reichel H, Rambausek M, Kokot F, Ritz E. The BsmI vitamin D-receptor polymorphism and secondary hyperparathyroidism [letter]. Nephrol Dial Transplant 1997 Aug;12(8):1771-1772.
Schuster VL, Seldin DW. Renal clearance, in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology, Vol. 1. New York, NY, Raven Press, 1985, pp 365-395.
Schwarz A, Keller F, Seyfert S, Poll W, Molzahn M, Distler A. Carpal tunnel syndrome: A major complication in long-term hemodialysis patients. Clin Nephrol 1984 Sep;22(3):133-137.
Schwarz Lausten G, Steen Jensen J, Olgaard K. Necrosis of the femoral head after renal transplantation. Acta Orthop Scand 1988;59(6):650-654.
Sebert JL, Fardellone P, Noel C, Cohen-Solal M, Bellony R, Marie A, Fournier A. Bone biopsy studies in the diagnosis and treatment of renal osteodystrophy. Contrib Nephrol 1988;64:49-57.
Serrano S, Marinoso ML, Torres A, Lorenzo V, Keysers U, Lloreta J, Nacher M, Garcia C, Ballester J, Diez A, Aubia J. Osteoblastic proliferation in bone biopsies from patients with end-stage chronic renal failure. J Bone Miner Res 1997 Feb;12(2):191-199.
Sethi D, Gower PE. Dialysis arthropathy, ß-microglobulin and the effect of dialyser membrane. Nephrol Dial Transplant 1988;3(6):768-772.
Sethi D, Naunton Morgan TC, Brown EA, Jewkes RF, Gower PE. Technetium-99-labelled methylene diphosphonate uptake scans in patients with dialysis arthropathy. Nephron 1990;54(3):202-207.
Setterberg L, Sandberg J, Elinder CG, Nordenstrom J. Bone demineralization after renal transplantation: Contribution of secondary hyperparathyroidism manifested by hypercalcaemia. Nephrol Dial Transplant 1996 Sep;11(9):1825-1828.
Sharman VL, Abrams SM, Adami S, Cattell WR, Chaput de Saintonge DM, Greenwood RN, Goodwin FJ, Hately W, Hattersley LA, Marsh FP, Morgan AG, Muir JW, O’Riordan JL, Papapoulos SE, Revell P, Tucker AK, Baker LR. Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients. Proc Eur Dial Transplant Assoc 1983;19:287-292.
Sharman VL, Brownjohn AM, Goodwin FJ, Hately W, Manning RM, O’Riordan JH, Papapoulos SE, Marsh FP. Long-term experience of alfacalcidol in renal osteodystrophy. Q J M 1982 Summer;51(203):271-278.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV. The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int 1993;43(2):436-442.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV. The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int 1993 Feb;43(2):436-442.
Shields RK, Cook TM. Effect of seat angle and lumbar support on seated buttock pressure. Phys Ther 1988 Nov;68(11):1682-1686.
Shimamatsu K, Maeda T, Harada A, Nishitani H, Onoyama K, Fujimi S, Omae T. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis. Nephron 1981;28(2):70-75.
Shin SK, Kim DH, Kim HS, Shin KT, Ma KA, Kim SJ, Kwak YS, Ha SK, Sherrard DJ. Renal osteodystrophy in pre-dialysis patients: Ethnic difference? Perit Dial Int 1999;19(Suppl 2):S402-S407.
Shiota E, Matsumoto Y, Nakamoto M. Open surgical treatment for dialysis-related arthropathy in the shoulder. J Shoulder Elbow Surg 2000 Mar-Apr;9(2):89-92.
Siede WH, Seiffert UB, Bundschuh F, Malluche HH, Schoeppe W. Alkaline phosphatase bone isoenzyme activity in serum in various degrees of micromorphometrically assessed renal osteopathy. Clin Nephrol 1980 Jun;13(6):277-281.
Simpson W, Ellis HA, Kerr DN, McElroy M, McNay RA, Ppeart KN. Bone disease in long-term haemodialysis: The association of radiological with histological abnormalities. Br J Radiol 1976 Feb;49(578):105-110.
Sivula A, Kuhlback B, Kock B, Kahri A, Wallenius M, Edgren J. Parathyroidectomy in chronic renal failure. Acta Chir Scand 1979;145(1):19-25.
Skroeder NR, Jacobson SH, Holmquist B, Kjellstrand P, Kjellstrand CM. Beta 2-microglobulin generation and removal in long slow and short fast hemodialysis. Am J Kidney Dis 1993 May;21(5):519-526.
Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest 1968 Aug;47(8):1865-1874.
Slatopolsky EA, Burke SK, Dillon MA, Bolin P, Boren K, Burke K, Al Dillon M, Domoto DT, Golper TA, Jones F, Kaupke CJ, Levinson R, Marx MA, Mattern W, Paller MS, Sirmon MD, Slatopolsky E, Stoltz R, Wagner J, Weinberg M, Wilkes B, Wombolt D, Van Gelder J. RenaGel a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55(1): 299-307
Slavotinek JP, Coates PT, McDonald SP, Disney AP, Sage MR. Shoulder appearances at MR imaging in long-term dialysis recipients. Radiology 2000 Nov;217(2):539-543.
Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 1998 May;13(5):1250-1255.
Smith AJ, Faugere MC, Abreo K, Fanti P, Julian B, Malluche HH. Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 1986;6(4):275-283.
Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991 Sep;73(3):516-524.
Somer E, Tucker CM. Patient life engagement, spouse marital adjustment, and dietary compliance of hemodialysis patients. J Compliance Health Care 1988;3(1):57-65.
Sommer R, Valen GJ, Ori Y, Weinstein T, Katz M, Hendel D, Korzets A. Sonographic features of dialysis-related amyloidosis of the shoulder. J Ultrasound Med 2000 Nov;19(11):765-770.
Spelsberg F. Experiences in transplantation of parathyroid tissue on the shunt-arm (secondary/tertiary hyperparathyroidism). Acta Chir Austriaca 1996;28(Suppl 124):44-45.
St. John A, Thomas M, Dick I, Young P, Prince RL. Parathyroid function in mild to moderate renal failure: Evaluation by oral calcium suppression test. J Clin Endocrinol Metab 1994 Jun;78(6):1436-1438.
Stamatakis MK, Pecora PG, Gunel E. Factors influencing adherence in chronic dialysis patients with hyperphosphatemia. J Renal Nutr 1997 Jul;7(3):144-148.
Stanbury SW, Lumb GA. Parathyroid function in chronic renal failure. A statistical survey of the plasma biochemistry in azotaemic renal osteodystrophy. Q J M 1966 Jan;35(137):1-23.
Cohen J. Statistical Power Analysis for the Behavioral Sciences (ed 2). New York, NY, Academic Press, 1988, 567 p.
Stehman-Breen CO, Sherrard D, Walker A, Sadler R, Alem A, Lindberg J. Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 1999 May;33(5):941-946.
Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000 Nov;58(5):2200-2205.
Stein A, Baker F, Moorhouse J, Walls J. Peritonitis rate: Traditional versus low calcium dialysate. Am J Kidney Dis 1995 Oct;26(4):632-633.
Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, Troughton J, Bircher G, Walls J. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997 Oct;52(4):1089-1095.
Stein G, Schneider A, Thoss K, Ritz E, Linke RP, Schaefer K, Sperschneider H, Abendroth K, Funfstuck R. Beta-2-microglobulin-derived amyloidosis: Onset, distribution and clinical features in 13 hemodialysed patients. Nephron 1992;60(3):274-280.
Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996 Oct;28(4):515-522.
Stim JA, Lowe J, Arruda JA, Dunea G. Once weekly intravenous calcitriol suppresses hyperparathyroidism in hemodialysis patients. ASAIO J 1995 Jul-Sep;41(3):M693-M698.
Stracke S, Jehle PM, Sturm D, Schoenberg MH, Widmaier U, Beger HG, Keller F. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999 Feb;33(2):304-311.
Sugimoto K, Dohi Y, Dohi K, Yonemasu K, Fujimoto J, Kanauchi M, Yamanaka F, Moriyama T, Ishikawa H. Serum levels of bone Gla-protein in normal humans and in patients with chronic renal failure. Miner Electrolyte Metab 1987;13(3):152-157.
Sulkova S, Valek A. Aluminum elimination in patients receiving regular dialysis treatment for chronic renal failure. Trace Elem Med 1991;8(Suppl 1):S26-S30.
Summers GW. Parathyroid update: A review of 220 cases. Ear Nose Throat J 1996;75(7):434-439.
Susanna F, Borsato N, Rossi B, Minello S, Ferlin G, Cascone C. Treatment of secondary hyperparathyroidism with low dose intermittent calcitriol in hemodialysis patients. Imaging and cost analysis. ASAIO J 1995 Jul-Sep;41(3):M688-M693.
Suzuki M, Hirasawa Y. Correction of metabolic acidosis and changes in plasma acetate levels in acetate and bicarbonate dialyses and acetate-free biofiltration. Contrib Nephrol 1994;108:114-120.
Suzuki M, Hirasawa Y. Renal osteodystrophy in early chronic renal failure. Contrib Nephrol 1980;22:28-38.
Swanson MR, Biggers JA, Remmers AR Jr, Sarles HE, Nelson RM, Fish JC. Results of parathyroidectomy for autonomous hyperparathyroidism. Arch Intern Med 1979 Sep;139(9):989-991.
Sy WM, Mittal AK. Bone scan in chronic dialysis patients with evidence of secondary hyperparathyroidism and renal osteodystrophy. Br J Radiol 1975 Nov;48(575):878-884.
Tagami T, Sakuma H, Matsumura K, Takeda K, Mori S, Takeuchi T, Nakano T. Evaluation of altered myocardial high energy phosphate metabolism in patients on maintenance dialysis using phosphorus-31 magnetic resonance spectroscopy. Invest Radiol 1998 Mar;33(3):171-176.
Tagliabue J, Farina M, Imbasciati E, Vergani C, Annoni G. BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients. Am J Clin Pathol 1999 Sep;112(3):366-370.
Takagi H, Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K. Experiences of total parathyroidectomy with forearm autografts for 254 patients with renal hyperparathyroidism. Acta Chir Austriaca 1996;28(Suppl 124):28-32.
Takagi H, Tominaga Y, Tanaka Y, Uchida K, Orihara A, Yamada N, Kawai M, Hayashi S, Taira N, Kano T. Total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 1988 Nov;208(5):639-644.
Takagi H, Tominaga Y, Uchida K, Yamada N, Ishii T, Morimoto T, Yasue M. Preoperative diagnosis of secondary hyperparathyroidism using computed tomography. J Comput Assist Tomogr 1982 Jun;6(3):527-528.
Takagi H, Tominaga Y, Uchida K, Yamada N, Kano T, Kawai M, Morimoto T. Comparison of imaging methods for diagnosing enlarged parathyroid glands in chronic renal failure. J Comput Assist Tomogr 1985 Jul-Aug;9(4):733-737.
Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Funahashi H, Mizuno S. Evaluation of image-diagnosing methods of enlarged parathyroid glands in chronic renal failure. World J Surg 1986 Aug;10(4):605-611.
Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Morimoto T. Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 1984 Jul;200(1):18-23.
Takagi H, Tominaga Y, Uchida K, Yamada N, Morimoto T, Yasue M. Image diagnosis of parathyroid glands in chronic renal failure. Ann Surg 1983 Jul;198(1):74-79.
Takebayashi S, Matsui K, Onohara Y, Hidai H. Sonography for early diagnosis of enlarged parathyroid glands in patients with secondary hyperparathyroidism. AJR Am J Roentgenol 1987 May;148(5):911-914.
Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 1996 Dec;28(6):3485-3487.
Tamanaha K, Mak RH, Rigden SP, Turner C, Start KM, Haycock GB, Chantler C. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children. Pediatr Nephrol 1987 Apr;1(2):145-149.
Tamarozzi R, Bedani PL, Scutellari PN, et al. Periosteal new bone in uraemic osteodystrophy. Skeletal Radiol 1984;11(1):50-53.
Tan CC, Harden PN, Rodger RS, Rowe PA, Spooner RJ, Junor BJ, Briggs JD. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 1996 May;11(5):851-853.
Tanaka Y, Seo H, Tominaga Y, Funahashi H, Matsui N, Takagi H. Factors related to the recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism. Surg Today 1993;23(3):220-227.
Tanaka Y, Tominaga Y, Funahashi H, Sato K, Numano M, Takagi H. Preoperative localization studies in secondary hyperplasia. Acta Chir Austriaca 1996;28(Suppl 124):14-16.
Tatler GL, Baillod RA, Varghese Z, Young WB, Farrow S, Wills MR, Moorhead JF. Evolution of bone disease over 10 years in 135 patients with terminal renal failure. Br Med J 1973 Nov 10;4(888):315-319.
Taylor A, Norman ME. Vitamin D metabolite profiles in moderate renal insufficiency of childhood. Pediatr Nephrol 1988 Oct;2(4):453-459.
Taylor J, Gunn A, Mactier RA, Henderson IS, Stewart WK. Parathyroidectomy in uraemic hyperparathyroidism: A clinical study. Scott Med J 1992 Feb;37(1):18-21.
Tessitore N, Venturi A, Adami S, Roncari C, Rugiu C, Corgnati A, Bonucci E, Maschio G. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Miner Electrolyte Metab 1987;13(1):38-44.
Tielemans C, Boelaert J, Vergauwe P, van Roost G, Segaert M, van Frachen B, Lenclud C. Deferoxamine does not increase the risk for bacteremia in hemodialysis patients. Nephron 1989;53(3):276-277.
Tielemans C, Dratwa M, Bergmann P, et al. Continuous ambulatory peritoneal dialysis vs haemodialysis = a lesser risk of amyloidosis? Nephrol Dial Transplant 1988;3:291-294.
Togashi K, Takahashi N, Ando K, Tsukamoto Y, Marumo F. Comparison of different parathyroid hormone radioimmunoassays in uremic patients with secondary hyperparathyroidism. Int J Artif Organs 1990 Feb;13(2):77-82.
Tomic Brzac H, Pavlovic D, Halbauer M, Pasini J. Parathyroid sonography in secondary hyperparathyroidism: Correlation with clinical findings. Nephrol Dial Transplant 1989;4(1):45-50.
Tominaga Y. Surgical management of secondary hyperparathyroidism in uremia. Am J Med Sci 1999 Jun;317(6):390-397.
Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 Mar-Apr;13(2):87-96.
Tominaga Y, Sato K, Numano M, Tanaka Y, Takagi H. Surgical treatment of renal hyperparathyroidism. Asian J Surg 1994;17(2):121-126.
Torregrosa JV, Ybarra J, Moreno A, Pons F, Oppenheimer F, Torres A. Vitamin D receptor gene polymorphisms and bone mineral density in patients on hemodialysis. Nephron 2000;84(4):381-382.
Torres A, Lorenzo V, Gonzalez-Posada JM. Comparison of histomorphometry and computerized tomography of the spine in quantitating trabecular bone in renal osteodystrophy. Nephron 1986;44(4):282-287.
Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 1995 May;47(5):1434-1442.
Torres A, Machado M, Concepcion MT, Martin N, Lorenzo V, Hernandez D, Rodriguez AP, Rodriguez A, de Bonis E, Gonzalez-Posada JM, Hernandez A, Salido E. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996 Nov;50(5):1726-1733.
Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet 1976 May 15;1(7968):1044-1047.
Trachtman H, Chan JCM, Boyle R, Farina D, Baluarte HJ, Chinchilli VM, Dresner JG, Feld LG. The relationship between calcium, phosphorus, and sodium intake, race, and blood pressure in children with renal insufficiency: A report of the growth failure in children with renal diseases (GFRD) study. J Am Soc Nephrol 1995;6(1):126-131.
Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution—Clinical benefits. Perit Dial Int 2000 Sep-Oct;20(5):516-523.
Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000 Mar;35(3):458-464.
Tsukamoto Y, Moriya R, Nagaba Y, Morishita T, Izumida I, Okubo M. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis 1995 Jun;25(6):879-886.
Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F. The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57(1):23-28.
Turner MW, Ardila M, Hutchinson T, Prichard S, Barre PE, Beauvais J, Kaye M. Sporadic aluminum osteomalacia: Identification of patients at risk. Am J Kidney Dis 1988;11(1):51-56.
Tzamaloukas AH, Kunzelman CL., Carroll LL, Scremin AE, Merlin TL, Avasthi PS, Bicknell JM. Carpel tunnel syndrome in patients on chronic hemodialysis. Nephrol Dial Transplant 1988;17(10):525-526, 541.
Uauy RD, Hogg RJ, Brewer ED, Reisch JS, Cunningham C, Holliday MA. Dietary protein and growth in infants with chronic renal insufficiency: A report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 1994 Feb;8(1):45-50.
Urena P, Eckardt KU, Sarfati E, Zingraff J, Zins B, Roullet JB, Roland E, Drueke T, Kurtz A. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomy. Nephron 1991;59(3):384-393.
Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, Souberbielle JC, Segre GV, Drueke TB, De Vernejoul MC. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 1995 Jun;10(6):932-939.
Van De Vyver FL, Bekaert AB, D’haese PC, et al. Serum, blood, bone and liver aluminum levels in chronic renal failure. Trace Elem Med 1986;3(2):52-61.
van den Bergh JP, Gelens MA, Klaassen HA, Kaufmann BG, Bottger WM, Verstappen VM. Efficacy and tolerance of three different calcium acetate formulations in hemodialysis patients. Neth J Med 1999 Nov;55(5):222-228.
Van der Niepen P, Sennesael J, Louis O, Verbeelen D. Effect of treatment with 1.25 and 1.75 mmol/l calcium dialysate on bone mineral density in haemodialysis patients. Nephrol Dial Transplant 1995 Dec;10(12):2253-2258.
van Diemen-Steenvoorde R, Donckerwolcke RA, Bosch R, Visser WJ, Raymakers JA, Duursma SA. Treatment of renal osteodystrophy in children with dihydrotachysterol and 24,25-dihydroxyvitamin D3. Clin Nephrol 1985 Dec;24(6):292-299.
Van Geertruyden J, Kinnaert P, Frederic N, Fuss M, Corvilain J. Effect of parathyroid surgery on cartilage calcification. World J Surg 1986 Feb;10(1):111-115.
Van Stone JC. Oral base replacement in patients on hemodialysis. Ann Intern Med 1984 Aug;101(2):199-201.
Van Stone JC, Mitchell A. Hemodialysis with base free dialysate. Proc Clin Dial Transplant Forum 1980;10:268-271.
van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J, Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. Kidney Int 1990;39:1012-1019.
Varghese Z, Moorhead JF, Farrington K. Effect of 24,25-dihydroxycholecalciferol on intestinal absorption of calcium and phosphate and on parathyroid hormone secretion in chronic renal failure. Nephron 1992;60(3):286-291.
Varghese Z, Moorhead JF, Wills MR. Plasma calcium and magnesium fractions in chronic-renal-failure patients on maintenance haemodialysis. Lancet 1973 Nov 3;2(7836):985-988.
Varghese Z, Moorhead JF, Wills MR. Plasma hydroxyproline fractions in patients with dialysis osteodystrophy. Clin Chim Acta 1981 Feb 19;110(1):105-111.
Velasquez-Forero F, Mondragon A, Herrero B, Pena JC. Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996;11 Suppl 3:58-64.
Velentzas C, Meindok H, Oreopoulos DG, Meema HE, Rabinovich S, Jones M, Sutton D, Rapoport A, deVeber GA. Visceral calcification and the CaXP product. Adv Exp Med Biol 1978;103:195-201.
Verzetti G, Navino C, Bolzani R, Galli G, Panzetta G, Ortensia A, Odone P, Cavagnino A, Agliata S, Cascone C, Susanna F, Cardelli R, Manzione AM, Vallino F, Alberghini E, et al. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: A cross-over multicentric study. Nephrol Dial Transplant 1998;13(4):955-961.
Villanueva AR, Jaworski ZF, Hitt O, Sarnsethsiri P, Frost HM. Cellular-level bone resorption in chronic renal failure and primary hyperparathyroidism. A tetracycline-based evaluation. Calcif Tissue Res 1970;5(4):288-304.
Vincent C, Revillard JP. Serum levels and urinary excretion of beta 2 microglobulin in patients under haemodialysis or after renal transplantation. Acta Clin Belg 1980;35 Suppl 1:31-39.
Vincent C, Revillard JP, Galland M, Traeger J. Serum beta2-microglobulin in hemodialyzed patients. Nephron 1978;21(5):260-268.
Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984;25(4):677-682.
Vincenti F, Hattner R, Amend WJ Jr, Feduska NJ, Duca RM, Salvatierra O Jr. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981 May 6;245(9):930-933.
Vlassopoulos D, Noussias C, Revenas K, Hadjilouka-Mantaka A, Arvanitis D, Tzortzis G, Hadjiconstantinou V. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism. Ren Fail 1999 Mar;21(2):199-207.
Vlcek J, Binswanger U, Keusch G, Zaruba J. Hyperparathyroidism after kidney transplantation: A retrospective case controlled study. Klin Wochenschr 1991 Sep 16;69(14):669-673.
Vogelgesang SA, Klipple GL. The many guises of amyloidosis: Clinical presentations and disease associations. Postgrad Med 1994;96(5):119-122, 126-127.
Voigts A, Felsenfeld AJ, Andress D, Llach F. Parathyroid hormone and bone histology: Response to hypocalcemia in osteitis fibrosa. Kidney Int 1984;25(2):445-452.
von Bonsdorff M, Sipila R, Pitkanen E. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. Scand J Urol Nephrol Suppl 1990;131:49-54.
Von Herrath D, Asmus G, Pauls A, et al. Renal osteodystrophy in asymptomatic hemodialysis patients: Evidence of a sex-dependent distribution and predictive value of serum aluminum measurements. Am J Kidney Dis 1986;8(6):430-435.
von Lilienfeld-Toal H, Gerlach I, Klehr HU, Issa S, Keck E. Immunoreactive parathyroid hormone in early and advanced renal failure. Nephron 1982;31(2):116-122.
Wada A, Sugihara M, Sugimura K, Kuroda H. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism. Radiat Med 1999 Jul-Aug;17(4):275-282.
Wadhwa NK, Howell N, Suh H, Cabralda T. Low calcium (2.5 mEq/l) and high calcium (3.5 mEq/l) dialysate in peritoneal dialysis patients. Adv Perit Dial 1992;8:385-388.
Walser M, Hill SB, Ward L, Magder L. A crossover comparison of progression of chronic renal failure: Ketoacids versus amino acids. Kidney Int 1993 Apr;43(4):933-939.
Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995 Nov;26(5):836-844.
Ward RA, Buscaroli A, Schmidt B, Stefoni S, Gurland HJ, Klinkmann H. A comparison of dialysers with low-flux membranes: Significant differences in spite of many similarities. Nephrol Dial Transplant 1997 May;12(5):965-972.
Ward RA, Schaefer RM, Falkenhagen D, Joshua MS, Heidland A, Klinkmann H, Gurland HJ. Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis. Nephrol Dial Transplant 1993;8(1):47-53.
Ward RA, Wathen RL, Williams TE, Harding GB. Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes. Kidney Int 1987 Jul;32(1):129-135.
Weed-Collins M, Hogan R. Knowledge and health beliefs regarding phosphate-binding medication in predicting compliance. ANNA J 1989 Jun;16(4):278-282, 285, discussion 2.
Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: A randomized controlled multicenter trial. Am J Kidney Dis 1995;25(3):452-460.
Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: Effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Perit Dial Int 1996 May-Jun;16(3):260-268.
Welk RA, Alix DR. A community hospital experience with total parathyroidectomy and autotransplantation for renal hyperparathyroidism. Am Surg 1987 Nov;53(11):622-627.
Wells SA Jr, Stirman JA Jr, Bolman RM 3d. Parathyroid transplantation. World J Surg 1977 Nov;1(6):747-756.
Welsh CL, Taylor GW, Cattell WR, Baker LR. Parathyroid surgery in chronic renal failure: Subtotal parathyroidectomy or autotransplantation? Br J Surg 1984 Aug;71(8):591-592.
White KS, Wilkinson CA, Nixon WP Jr, Almkuist RD 2d. Total parathyroidectomy and forearm autotransplantation for chronic renal failure: A useful tool for the general surgeon in private practice. South Med J 1986 Jul;79(7):844-846.
Wibell L, Grimelius L, Johansson H. Explorative parathyroidectomy before and after kidney transplantation. Scand J Urol Nephrol Suppl 1977;(42):153-158.
Wiecek A, Kokot F, Kochanska-Dziurowicz A, Grzeszczak W, Zukowska-Szczechowska E. Serum ß-microglobulin levels in kidney transplant patients. Transplant Proc 1989;21(1 II):2050-2051.
Wilhelm M, Passlick J, Busch T, Szydlik M, Ohnesorge FK. Scalp hair as an indicator of aluminium exposure: Comparison to bone and plasma. Hum Toxicol 1989 Jan;8(1):5-9.
Willeke F, Senninger N, Lamade W, Grauer A, Hinz U, Buhr HJ, Herfarth CH. Risk factor analysis in surgery for renal hyperparathyroidism. Acta Chir Austriaca 1996;28(Suppl 124):23-25.
Williams AJ, Dittmer ID, McArley A, Clarke J. High bicarbonate dialysate in haemodialysis patients: Effects on acidosis and nutritional status. Nephrol Dial Transplant 1997 Dec;12(12):2633-2637.
Williams B, Vennegoor M, O’Nunan T, Walls J. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure. Nephrol Dial Transplant 1989;4(8):725-729.
Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: A prospective, randomized, controlled trial. Q J M 1991 Oct;81(294):837-855.
Wills MR, Fairney A, Varghese Z, Tatler GL, Baillod RA, Moorhead JF. Serum parathyroid hormone concentration in chronic renal failure patients on maintenance haemodialysis. Clin Chim Acta 1974 Nov 20;57(1):83-89.
Wilmink JM, Bras J, Surachno S, van Heyst JL, van der Horst JM. Bone repair in cyclosporin treated renal transplant patients. Transplant Proc 1989 Feb;21(1 Pt 2):1492-1494.
Wilson L, Felsenfeld A, Drezner MK, Llach F. Altered divalent ion metabolism in early renal failure: Role of 1,25(OH)2D. Kidney Int 1985 Mar;27(3):565-573.
Wingen AM, Fabian-Bach C, Mehls O. Multicentre randomized study on the effect of a low-protein diet on the progression of renal failure in childhood: One-year results. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Miner Electrolyte Metab 1992;18(2-5):303-308.
Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997 Apr 19;349(9059):1117-1123.
Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulak JA, Hricik DE. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994 Dec 15;58(11):1186-1189.
Wortman PM. Lessons from the meta-analysis of quasi-experiments, in Bryant FB, Edwards J, Tindale RS, Posavac EJ, Heath L, Henderson E, Suarez-Balcazar Y (eds): Methodological Issues in Applied Social Psychology. New York, NY, Plenum Press, 1992, pp 65-81.
Xiao HW. An approach to the appropriate dosage of essential amino acids in the treatment of chronic renal failure. J Tongji Med Univ 1991;11(4):240-243.
Yalcinkaya F, Ince E, Tumer N, Ensari A, Ozkaya N. Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis. Pediatr Int 2000 Feb;42(1):53-57.
Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996;19(5):549-555.
Yanitski AE. Compliance of the hemodialysis patient. AANNT J 1983 Apr;10(2):11-16.
Yates LA, Soffer O, Gropper SS. Phosphate binders and mineral status of adult renal disease patients on hemodialysis. Dial Transplant 2000 May;29(5):268-275.
Yen TC, Tzen KY, Chen KS, Tsai CJ. The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related beta 2-microglobulin amyloid. Eur J Nucl Med 2000 Jan;27(1):56-61.
Yokoyama K, Shigematsu T, Tsukada T, Ogura Y, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int 1998 Feb;53(2):454-458.
Yu I, DeVita MV, Komisar A. Long-term follow-up after subtotal parathyroidectomy in patients with renal failure. Laryngoscope 1998 Dec;108(12):1824-1828.
Yumita S, Suzuki M, Akiba T, Akizawa T, Seino Y, Kurokawa K. Levels of serum 1,25(OH)2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med 1996 Sep;180(1):45-56.
Zanella MT, Silva MC, Peres RB, Ferreira SR, Draibe SA, Vieira JG. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure. Braz J Med Biol Res 1990;23(3-4):235-243.
Zaraca F, Mazzaferro S, Catarci M, Saputelli A, Alo P, Carboni M. Prospective evaluation of total parathyroidectomy and autotransplantation for the treatment of secondary hyperparathyroidism. Arch Surg 1999 Jan;134(1):68-72.
Zdon MJ, Iliopoulos JI, Thomas JH, Pierce GE, Hermreck AS, Friesen SR. Subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery 1984 Dec;96(6):1103-1108.
Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991 Jan 10;324(2):78-84.
Zevin D, Davidovich Z, Gafter U, Weinstein T, Chaimoff C, Levi J. Surgical management of secondary hyperparathyroidism in patients with renal failure. Isr J Med Sci 1983 Jun;19(6):559-562.
Zhong A, Billa V, Rotstein LE, Wong PY, Margman JM, Vas SI, Oreopoulos DG. Recurrence of hyperparathyroidism after total parathyroidectomy and autotransplantation in peritoneal dialysis patients. Perit Dial Int 2000 Mar;20(2):200-208.
Zingraff J, Beyne P, Urena P, Uzan M, Nguyen Khoa Man, Descamps-Latscha B, Drueke T. Influence of haemodialysis membranes on beta 2-microglobulin kinetics: In vivo and in vitro studies. Nephrol Dial Transplant 1988;3(3):284-290.
Zingraff J, Noel LH, Bardin T, Kuntz D, Dubost C, Drueke T. Beta 2-microglobulin amyloidosis: A sternoclavicular joint biopsy study in hemodialysis patients. Clin Nephrol 1990 Feb;33(2):94-97.
Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000 Jun;89(6):666-671.
Zucchelli P, Cartizone L, Casanova S, et al. Renal osteodystrophy in CAPD patients. Miner Electrolyte Metab 1984;10(5):326-332.